



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/53, 15/82, 15/81, 9/06, 1/21, 1/19, 5/10, A01H 5/00, C12Q 1/26		A1	(11) International Publication Number: WO 99/06571
			(43) International Publication Date: 11 February 1999 (11.02.99)
(21) International Application Number: PCT/US98/15844 (22) International Filing Date: 30 July 1998 (30.07.98) (30) Priority Data: 60/054,268 30 July 1997 (30.07.97) US 09/124,541 29 July 1998 (29.07.98) US (71) Applicant: THE CURATORS OF THE UNIVERSITY OF MISSOURI [US/US]; 509 Lewis Hall, Columbia, MO 65211 (US). (72) Inventor: MORRIS, Roy, O.; 4938 Bethel Street, Columbia, MO 65203 (US). (74) Agents: BLOSSER, G., Harley et al.; Senniger, Powers, Leavitt & Roedel, 16th floor, One Metropolitan Square, St. Louis, MO 63102 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: CYTOKININ OXIDASE			
(57) Abstract			
<p>An isolated protein which exhibits cytokinin oxydizing activity selected from the group consisting of SEQ. ID No. 1, a protein having an amino acid sequence which includes the amino acid sequence of SEQ. ID No. 1, a protein having an amino acid sequence which includes a portion of the amino acid sequence of SEQ. ID No. 1, the included portion being at least about 20 amino acid residues in length and conferring the cytokinin oxidizing activity on the protein, and a protein including an amino acid sequence with at least about 65 % sequence identity to SEQ. ID No. 1, the remainder of amino acid residues being conservatively substituted. Nucleic acids encoding proteins which exhibit cytokinin oxidizing activity and related products and methods are also disclosed.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

CYTOKININ OXIDASE

BACKGROUND OF THE INVENTION

The present invention relates to a purified plant cytokinin oxidizing enzyme (*ckx1*) from *Zea mays*, the complete amino acid sequence of which has been
5 elucidated, and to isolated nucleotide sequences encoding the enzyme. The invention further relates to novel methods for moderating the concentration of the enzyme and similar enzymes in plants in order to affect plant cell growth and death. Applications of the invention
10 include the regulation of the production of *ckx1* in plant roots to affect pathogenesis, the regulation to alter plant habit, and the bulk production of *ckx1* enzyme for use in a plant biochemical assay.

Plant cytokinins are a class of plant hormones
15 which, when combined with auxin, control cell division, promote shoot development from callus, release lateral buds from dormancy, and regulate plant structure and growth in a variety of ways. The naturally occurring active cytokinins in most higher plants are free-base
20 zeatin (6-(4-hydroxy-3-methylbut-*trans*-2-enylamino)purine) (hereinafter Z), and its 9-riboside (hereinafter ZR). Plant tissues normally contain, therefore, Z, ZR, and smaller amounts of N⁶-(Δ^2 -isopentenyl)adenine (hereinafter, iP) derived from
25 biosynthetic precursors. Elevated cytokinin levels are associated with the development of seeds in higher plants, and have been demonstrated to coincide with maximal mitotic activity in the endosperm of developing maize kernels and other cereal grains. Exogenous
30 cytokinin application (via stem injection) has been shown to directly correlate with increased kernel yield in maize. In addition, plant cells transformed with the *ipt* gene from *Agrobacterium tumefaciens* (encoding a

dimethylallylpyrophosphate:5'-AMP transferase capable of increasing cellular production of Z and ZR) showed increased growth corresponding to an increase in endogenous cytokinin levels upon induction of the enzyme.

5 Thus, given the biosignificance of cytokinins to the growth of plants, the ability to manipulate cytokinin levels in higher plant cells is of great commercial and scientific interest.

10 The action of cytokinin oxidase is a major method of effective cytokinin catabolism in plant cells. This inactivation of cytokinin is accomplished by the oxidative removal of the side chain from cytokinin free bases (or their ribosides) in the presence of molecular oxygen. An example of this reaction with iP is shown in 15 Figure 1a. Although the exact chemical mechanism for this reaction is unknown, it is suspected that the enzyme is reduced during the deprotonation of iP to N⁶-(Δ^2 -isopentenylimino)purine. The purine is then hydrolyzed into adenine and intermediate 3-methyl-2-butenal (Figure 20 1b).

While the electron acceptor responsible for reoxidizing the reduced enzyme in plant cells is not known, molecular oxygen can do so *in vitro*. Alternatively, the reduced enzyme may be reoxidized *in* 25 *vitro* by intermediates such as Cu⁺²/imidazole complexes or the artificial electron acceptor dichlorophenolindophenol (DCPIP).

Cytokinin oxidases are known to remove cytokinins from plant cells after cell division, and have also been 30 postulated to be involved in the senescence process. Cytokinin oxidase activities have been shown to positively correlate to the mitosis of endosperm cells in maize kernels, along with the increase in natural cytokinin concentrations. Oxidase activity increases 35 shortly after the increase in endogenous cytokinin levels. A similar correlation was demonstrated with artificially increased cytokinin levels in transgenic

tobacco. Thus, expression of cytokinin oxidases is thought to be involved in the maintenance of hormonal homeostasis in developing plant cells. Because cytokinin oxidases appear to be substrate-inducible, they act in a negative regulatory fashion to reduce elevated cytokinin levels back to basal values. This substrate induction of cytokinin oxidase activity is a significant barrier to potential commercial applications which attempt to manipulate cytokinin levels in transgenic plants through increased cytokinin production.

Cytokinin oxidases have been discussed for a number of plant species, including *Vinca rosea*, beans (*Phaseolus vulgaris* and *lunatus*), wheat (*Triticum aestivum*), tobacco (*Nicotiana tabacum*), *Dianthus caryophyllus*, soy (*Glycine max*), and maize (*Zea mays*). All of these plant cytokinin oxidases have a similar substrate preference for iP and Z, but show limited or no reactivity with bulky, reduced, or aromatic side chain cytokinins. All also exhibit enhanced activity in the presence of copper plus imidazole. However, these enzymes show substantial variation in both specific activity and molecular weight. This is thought to be linked to the occurrence of glycosylated and unglycosylated variants of the protein, both between and within species.

In the case of the glycosylated cytokinin oxidase, the heavily glycosylated protein may present a carbohydrate-rich surface, preventing antibody formation against peptide epitopes. The glyco-epitopes to which antibodies are raised under these conditions are non-specific, and may prevent isolation of the protein, or clones containing the gene which encodes it, via immunochromatography or other immunology-based means. An earlier reported attempt to isolate the gene for maize

cytokinin oxidase (*ckx1*) by immunoscreening of maize cDNA library expression products (Burch, 1992) was unsuccessful.

As demonstrated, the full amino acid sequence and
5 encoding DNA for a cytokinin oxidase has been a long
sought after goal in modern plant physiology.

SUMMARY OF THE INVENTION

It is therefore an object of the present invention
to provide a means by which recombinant cytokinin oxidase
10 may be produced in quantity so that the effects of
cytokinin oxidase on plant growth and metabolism may be
studied. It is also an object of the present invention to
provide a means for the modification of cytokinin oxidase
production in plant cells, *in vivo*, in order to modulate
15 the endogenous cytokinin level of plant cells to effect
altered pathogen resistance and plant growth properties.

The present invention, therefore, is directed to a
novel, isolated and substantially purified plant
cytokinin oxidizing enzyme, (*ckx1*), having a molecular
20 weight most preferably of about 60 kD, a sequence length
of from about 505 to 565 amino acid residues, preferably
525 to 545 amino acid residues, and most preferably 534
amino acid residues, and having cytokinin inactivating
activity. The present invention is also directed to a
25 protein having an amino acid sequence which includes the
amino acid sequence of *ckx1* (SEQ. ID NO. 1). The
invention is directed as well to a protein which has
cytokinin inactivating activity and which includes a
portion of the amino acid sequence of *ckx1* at least about
30 20 amino acid residues in length, where the included
portion of the *ckx1* sequence confers the cytokinin
inactivating activity on the protein. The invention is
directed to proteins which have cytokinin inactivating
activity and have at least about 65% sequence identity to

ckx1 and most preferably at least about 95% sequence identity to *ckx1*, with the remaining amino acids being conservatively substituted.

The invention is directed, moreover, to
5 substantially isolated nucleic acid polymers encoding *ckx1* or a cytokinin oxidizing homolog thereof. The nucleic acid polymer most preferably has a nucleic acid sequence of SEQ. ID NO. 3 or the predictable variants thereof described in SEQ. ID NO. 10. The invention is
10 also directed to a substantially isolated nucleic acid polymer which contains a portion of SEQ. ID NO. 2, SEQ. ID NO. 3, or a nucleic acid polymer described by SEQ. ID NO. 10, the portion being at least 60 bp in length. In addition, the invention is directed to nucleic acid
15 polymers which are able to hybridize with SEQ. ID NO. 2, SEQ. ID NO. 3, or a nucleic acid polymer described by SEQ. ID NO. 10, under conditions of 0.5X to 2X SSC buffer, 0.1% SDS, and a temperature of 55-65°C. Nucleic acid polymers which encode cytokinin oxidases and meet the
20 above requirements encode proteins of sufficient similarity to *ckx1* to be generally recognized as equivalents of *ckx1* among those skilled in the biochemical arts.

The invention is also directed to a host cell
25 incorporating a vector containing the aforementioned DNA, and to a method for producing *ckx1* or a homolog thereof using such a host cell. The method preferably comprises first ligating DNA encoding the aforementioned *ckx1* or a segment or homolog thereof and an appropriate promoter
30 (such as the *RB7* root-specific promoter, Conkling, M.A., et al., U.S. Pat. No. 5,459,252; or *CaMV35S* promotor, Odell, 1985), or a combination of promoters (Hoffman, Patent No. 5,106,739) 3) into an appropriate DNA vector (for instance, pBIN19 for use in *Agrobacterium*
35 *tumefaciens*). The vector construct may then be directly

transformed into a host cell, such as *Pichia pastoris* (described in Example 2). It may also be incorporated into a secondary vector for transformation into a host cell, such as *Agrobacterium tumefaciens*, and transformed
5 into a plant cell host (described in Example 4 with *Nicotiana tabacum*).

Alternatively, for production of larger amounts of the enzyme, the DNA encoding *ckx1*, or a portion thereof, may be transformed into *Pichia*, according to the methods
10 described in Example 2, or in Su, et al., 1996 and Skory, et al., 1996. When transformed into *Pichia spp.*, *ckx1* is secreted into the culture medium because of the presence of a secretory signal peptide at the N-terminus of the *ckx1* coding region. Thus, active enzyme may be readily
15 purified from bulk *Pichia* cultures without a lysing step. *ckx1* produced in such a manner may be used in a biochemical assay to determine unknown concentrations of cytokinin in biological samples, according to the method of Example 3.

20 A plant host cell generated by the above method may be regenerated into an entire plant. Depending on the promoter used in the vector construct, *ckx1* may be produced constitutively or by induction through natural or artificial environment factors. Plants transformed
25 with vectors containing tissue-specific or trauma-specific promoters and a sequence encoding *ckx1* can exhibit altered resistance to certain cytokinin-linked plant pathologies, such as infection by certain nematodal or fungal species.

30 The discoveries described herein provide an important analytical tool for, and a critical link in, the development of methods by which the manipulation of cytokinin oxidase activity may be used to either inhibit or enhance a variety of cell growth functions in plants
35 in a desired manner. Possible uses include the

development of commercial plants with increased grain production, disease resistance, or with more desirable secondary growth characteristics. The enzyme and its encoding nucleic acids have important uses in the study of plant cell growth cycles and senescence. In addition, many other pharmaceutical and agricultural uses for *ckx1* and its gene may be discovered. The enzyme, methods of expressing the enzyme, and methods for its use are described in greater detail below.

Other features and objects of the present invention will be in part apparent to those skilled in the art and in part pointed out hereinafter.

BRIEF DESCRIPTION OF THE FIGURES,

SEQUENCE IDENTIFICATIONS, AND DEFINITIONS

The invention is further disclosed and illustrated by the accompanying figures.

FIG. 1a & b show an exemplary reaction catalyzed by cytokinin oxidase (Brownlee, 1975), and its putative mechanism as described above, based on Hare, 1994.

FIG. 2 shows agarose gel electrophoresis of RT-PCR DNA fragments which demonstrate that the introns of the *ckx1* gene have been correctly identified.

FIG. 3 shows the standard spectrophotometric absorbance curve (590 nm) obtained when using *ckx1* to assay cytokinin concentrations in solution.

FIG. 4 is a diagram of DNA plasmid pJL7.

FIG. 5 is a diagram of DNA plasmid pBI121.

FIG. 6 is a diagram of DNA plasmid pROM8.

FIG. 7 is a diagram of DNA plasmid pROM9.

FIG. 8 is a diagram of DNA plasmid pROM22.

FIG. 9 is a diagram of DNA plasmid pROM24.

FIG. 10 is a diagram of DNA plasmid pROM26.

FIG. 11 is a diagram of DNA plasmid pROM28.

FIG. 12 is a diagram of DNA plasmid pROM29.

FIG. 13 is a diagram of DNA plasmid pROM30.

FIG. 14 is a diagram of DNA plasmid pROM32.

FIG. 15 is a diagram of DNA plasmid pROM43.

All Sequence Identification abbreviations of amino acids and nucleotides conform to USPTO and WIPO standards.

5 SEQ. ID NO. 1 lists the amino acid sequence of naturally occurring *ckx1* derived from *Zea mays*. This sequence was predicted from the genomic DNA derived nucleotide sequence encoding *ckx1*.

10 SEQ. ID NO. 2 lists the genomic DNA sequence encoding *ckx1*, including introns.

SEQ. ID NO. 3 lists the coding DNA sequence for *ckx1*, with introns excluded. This sequence has been reconstructed in pROM22 of Example 2.

15 SEQ. ID NO. 4 lists the amino acid sequence of an internal tryptic digest fragment of *ckx1*.

SEQ. ID NO. 5 lists the amino acid sequence of an internal tryptic digest fragment of *ckx1*.

20 SEQ. ID NO. 6 lists the nucleic acid sequence of a degenerate DNA probe used to isolate the genomic DNA encoding *ckx1*, as described in Example 1. Note that the residues designated "n" in the sequence are the artificial base inosine (I). Normal conventions have been followed for the indication of degeneracies in the sequence.

25 SEQ. ID NO. 7 lists the nucleic acid sequence of a degenerate DNA probe used to isolate the genomic DNA encoding *ckx1*, as described in Example 1. Note that the residues designated "n" in the sequence are the artificial base inosine (I). Normal conventions have been followed for the indication of degeneracies in the sequence.

30 SEQ. ID NO. 8 lists the nucleic acid sequence of a degenerate DNA probe used to isolate the genomic DNA

encoding *ckx1*, as described in Example 1. Note that the residues designated "n" in the sequence are the

artificial base inosine (I). Normal conventions have been followed for the indication of degeneracies in the sequence.

5 SEQ. ID NO. 9 lists the nucleic acid sequence of a degenerate DNA probe used to isolate the genomic DNA encoding *ckx1*, as described in Example 1. Note that the residues designated "n" in the sequence are the artificial base inosine (I). Normal conventions have been followed for the indication of degeneracies in the
10 sequence.

SEQ. ID NO. 10 lists the degenerate DNA sequence encoding *ckx1*. As is well known in the art, the several DNA molecules indicated by this group encode a protein with the amino acid sequence of SEQ. ID NO. 1, also known
15 as *ckx1*. This group follows the conventional rules of degeneracy in the genetic code. Special modifications necessary for expression in certain organisms which do not follow these conventions could easily be made by an individual of ordinary skill in the art.

20 SEQ. ID NO. 11 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 12 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

25 SEQ. ID NO. 13 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 14 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 15 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

30 SEQ. ID NO. 16 lists the sequence of a synthetic primer used in the PCR removal of introns in example 2.

SEQ. ID NO. 17 lists the sequence of a synthetic linker construct used in example 2.

35 SEQ. ID NO. 18 lists the sequence of a synthetic linker construct used in example 2.

SEQ. ID NO. 19 lists the sequence of a synthetic primer used in PCR to obtain the tobacco RB7 promoter in example 4.

5 SEQ. ID NO. 20 lists the sequence of a synthetic primer used in PCR to obtain the tobacco RB7 promoter in example 4.

10 As used herein, a "substantially purified protein" means that the protein is separated from a majority of host cell proteins normally associated with it or that the protein is synthesized in substantially purified form, such synthesis including expression of the protein in a host cell from a nucleic acid polymer exogenously introduced into the cell by any suitable gene-therapy delivery means.

15 A "substantially isolated nucleic acid polymer" means that the mixture which comprises the nucleic acid polymer of interest is essentially free of a majority of other nucleic acid polymers normally associated with it. A "nucleic acid polymer" includes a polymer of
20 nucleotides or nucleotide derivatives or analogs, including for example deoxyribonucleotides, ribonucleotides, etc. Genomic DNA, cDNA and mRNA are exemplary nucleic acid polymers.

25 The terms "regulate transcription," "modify transcription," "regulate production," and "modify production," is intended to include promotion and/or repression of transcription or mRNA or production/translation of a protein.

30 The term "expression regulatory sequence" means a nucleic acid polymer sequence ligated to a protein encoding sequence which, when introduced into a host cell, either induces or prevents expression of that protein. These sequences may or may not also encode

proteins used in their regulatory mechanism. Examples of expression regulatory sequences include the *CaMV* promoter, the *ocs* terminator, and the *tet* operator sequences.

- 5 The term "gene" is intended to include both endogenous and heterologous genes, and specifically, both genomic DNA which encodes a target protein in a naturally occurring cell, and also cDNA encoding the target protein, for example, wherein the cDNA is a part of a
10 nucleic acid construct such as a plasmid vector or virus which has been introduced into a cell or a cDNA produced by RT-PCR.

- The term "vector" is intended to include any physical or biochemical vehicle containing nucleic acid
15 polymers of interest, by which those nucleic acid polymers are transferred into a host cell, thereby transforming that cell with the introduced nucleic acid polymers. Examples of vectors include DNA plasmids, viruses, particle gun pellets, and bacteria such as
20 *Agrobacterium tumefaciens*. The term "primary vector" is intended to mean the first vector used in a transformation series, either as one step (e.g. a plasmid used to transform a yeast cell), or with a "secondary vector" (e.g. a plasmid used to transform *Agrobacterium*
25 *tumefaciens*, which is later used to transform a plant cell).

- The term "host cell" is intended to mean the target cell for vector transformation, in which the transferred nucleic acid polymer will be replicated and/or
30 expressed.

- The term "conservative substitution," in the context of amino acid sequences, means the substitution of one amino acid in the sequence with another with a side chain of similar size and charge. An example of a conservative
35 substitution would be substituting glutamine for asparagine. Conservative substitutions in a protein

sequence which would be expected to have minimal to no impact on protein structure or function can be readily devised by a person of ordinary skill in the biochemical arts.

5 The term "plant products" means any cellular material produced by a plant, especially those which may be used for propagation of the plant. Plant products include seeds, rhizomes, leaves, meristem, roots, and buds.

10 The term "SSC buffer" means a solution of 8.765 g NaCl and 4.41 g sodium citrate in 1 liter of water, pH adjusted to 7.0 by titrimetric addition of 10 N NaOH solution.

15 The contents of each of the references cited herein are being incorporated by reference in their entirety.

DETAILED DESCRIPTION OF THE INVENTION

20 The present invention relates to newly sequenced cytokinin oxidase isolated from the maize plant, *Zea mays*, designated *ckx1*, which exhibits a substrate specific cytokinin oxidizing activity. The enzyme has been linked to the development and maturation of kernels in maize, as well as the senescence of plant tissues. The control of these plant functions appears to be achieved by the degradation of endogenous and exogenous cytokinin concentrations. Because *ckx1* efficiently oxidizes

25 unsaturated-side-chain free cytokinins and their ribosides, such as iP, Z, and ZR (which also induce production of the enzyme when applied exogenously or endogenously), it is thought that *ckx1* rigorously

30 controls the availability of these active cytokinins as a part of plant growth regulation.

35 During the course of developing the claimed invention, the applicant encountered several difficulties which may explain why the search for a cytokinin oxidase gene has been heretofore unsuccessful. The protein is

expressed at very low levels, and only at certain periods of the plant growth cycle. Therefore, screening a λ -cDNA maize library in *E. coli* may not yield *ckx1* simply because the gene was not expressed, or not expressed in detectable amounts, when the library was taken. Also, isolation of the protein may have been a problem for some researchers, since its active form does not survive gel filtration. Only through the development of his own screening process, described in Example 1, was the applicant able to isolate the protein in sufficient purity for tryptic digestion and subsequent sequencing.

Even after the protein was purified, obtaining the gene sequence for *ckx1* proved to be difficult.

Apparently, the N-terminal end of *ckx1* is blocked, so a straightforward Edman degradation determination of its N-terminal sequence was impossible. Only small, internal sequences were determinable after tryptic digestion of the protein, SEQ. ID NO. 4 & 5. Because the location of these fragments in the protein's amino acid sequence was unknown, several problems had to be overcome in order to successfully probe the *Zea mays* genome for the *ckx1* gene, as detailed in Example 1. The small size of the sequenced peptides necessitated using a "bookended" criteria (one probe at either end of the replicated DNA) in order to eliminate non-*ckx1* DNA from either side of the *ckx1* gene. One could be reasonably certain that the DNA between two probes would be part of the *ckx1* gene. A hybridization/amplification product size criteria of 300 bp was also necessary in order to distinguish between dimerized degenerate primers and PCR products. A simple degenerate strategy was unlikely to work because of the high degeneracy inherent in the particular amino acid sequences available from the tryptic peptides. Initially, when a standard degenerate nucleotide strategy was used, utilizing all possible oligonucleotides encoding the interior amino acid sequences, the low concentration of

specifically binding primer was not sufficient for the initiation of PCR amplification. The applicant was able to overcome this problem only by using inosine containing degenerate probes with a broader specificity. Also, several of the degenerate probes were too close together to yield products of the target size, or not in the right order in the gene to produce "bookended" products. Only probes SEQ ID NO. 6, 7, 8, & 9 proved to be of use in isolating the *ckx1* gene.

The identity of the isolated gene was verified by two independent methods. First, it was verified by testing the affinity of goat antisera to an *Escherichia coli* produced translation of SEQ. ID NO. 3 for *ckx1* in maize kernel extracts, as per Example 1. Second, it was confirmed by expressing SEQ. ID No. 3 in *Pichia pastoris* resulting in the secretion of active cytokinin oxidase as per Example 2.

SEQ. ID NO. 2 lists the complete genomic DNA sequence of *ckx1*, which yields the glycosylated form of the protein when expressed in *Zea mays*. The predicted location of the introns in the genomic sequence was verified using the reverse transcriptase- polymerase chain reaction to find the actual transcribed length of RNA, as per Example 1. SEQ. ID NO. 3 lists the coding DNA sequence for *ckx1*, which yields the amino acid sequence set forth in SEQ. ID NO. 1.

The state of the art of molecular biology is now sufficiently advanced that minor alterations can be made to a DNA sequence with relative ease and precision. A moderately skilled laboratory technician can follow the directions of one of the commercially available site-directed mutagenesis kits (for instance, the GeneEditor™ offered by Promega Corp., Madison, Wisconsin) to effect any number of changes to a DNA nucleotide sequence. Also well known are the general rules governing the genetic code, by which triplet nucleotide codons are translated

into an amino acid sequence by standard biochemical processes. Thus, the applicant considers the group of DNA sequences denoted by the consensus sequence of SEQ. ID NO. 10, which code for the amino acid sequence of *ckx1* in

5 SEQ. ID. NO. 1, to be within the present invention. Although some variation in the genetic code and the GC% content occurs amongst some phyla, the rules governing these variations have also been well documented, and are within the reasonable skill of one versed in the
10 molecular genetic arts. Thus, the applicant also considers any other nucleic acid sequence which encodes the amino acid sequence SEQ. ID NO. 1 to be within the scope of the present invention.

In addition, although the understanding of the field
15 of protein biochemistry is not as complete as that of molecular genetics, the person of ordinary skill in the art of biochemistry is capable of predicting, with reasonable certainty, when certain substitutions to the primary amino acid sequence structure of a protein will
20 not result in any appreciable modification of a protein's structure or function. Such conservative substitutions are made by replacing an amino acid in the sequence with another containing a side chain with like charge, size, and other characteristics. For instance, the amino acid
25 alanine, which has a small nonpolar methyl side chain, generally can be replaced by glycine, an amino acid which has a small nonpolar hydrogen side chain, without any noticeable effects. Likewise, the amino acid asparagine, with a moderately bulky, polar ethamide side chain,
30 usually can be replaced with glutamine, which has a moderately bulky, polar propamide side chain, without noticeable effects. To the extent that such conservative substitutions can be made while retaining 65%, preferably 80% or more identity to SEQ. ID NO. 1 and cytokinin
35 oxidizing activity, such altered proteins are within the scope of the present invention.

Cytokinin oxidases are known to exist in a variety of non-glycosylated and glycosylated forms in several species of higher plants, including maize. This modification is thought to be involved in

5 compartmentalizing cytokinin oxidases for various uses inside and outside the cell. The extent of glycosylation of the enzyme may also account for the wide variety of molecular weights observed between the cytokinin oxidases of various species. However, because substrate

10 specificity, a requirement of molecular oxygen for activity, and copper concentration reaction rate effects *in vitro* are highly conserved among all higher plant cytokinin oxidases, a common domain and active site structure is believed responsible for the cytokinin

15 oxidizing activity of all enzymes. Thus, the present invention is also directed to a protein which exhibits cytokinin oxidizing activity and which contains an amino acid sequence at least about 20 amino acids in length which is 90% identical (or would be identical with

20 conservative amino acid substitutions) to a similarly sized portion of SEQ. ID NO. 1.

Another object of the current invention is the regulated production of *ckx1* in various host cells, either for later bulk isolation, or regulated

25 intracellular production. For instance, *ckx1* may be produced in unglycosylated form in prokaryotes, such as *E. coli*, as illustrated in example 1. More preferably, the protein may be produced in eukaryotes, as illustrated by the *Pichia* production of example 2. An added benefit

30 of producing the protein in *Pichia* is that the protein is secreted into the culture media where it may be readily purified. Alternatively, the protein may be produced in higher eukaryotes, more preferably plants, such as the *Nicotiana* constructs of example 4 either as the

35 glycosylated or non-glycosylated forms. Other examples of suitable host plant cells include *Zea mays*,

Arabidopsis thaliana, *Brassica* spp, and *Oryza sativa*. As illustrated, *ckx1* can be produced in plants either in an unregulated fashion, as shown here under the *CaMV* promoter, regulated by an artificial stimuli, as shown here under a tet operator combined with a *CaMV* promoter, and regulated by an environmental stimuli, as shown here under the *RB7* promotor, which induces root-specific production of a protein in response to nematodal attack.

The several aspects of the present invention, including the *ckx1* protein and the nucleic acid polymers which encode it, the cytokinin oxidizing activity of enzymes such as the *ckx1* enzyme, and the regulation of cytokinin levels in plant cells by *ckx1*, collectively enable several practical applications, including both agricultural and research uses.

The applicant has devised an application for bulk cytokinin oxidase which greatly facilitates plant physiology research. Cytokinin oxidase can be reoxidized after oxidizing cytokinins by the synthetic oxidizing agent dichlorophenolindophenol (DCPIP). DCPIP demonstrates a reduced absorbance at 590 nm upon reduction, which can be spectrophotometrically quantified. The cytokinin concentration in a sample may be determined indirectly by measuring the decrease in oxidized DCPIP as *ckx1* oxidizes the cytokinins present in the sample. More sensitive redox dyes are also available to increase the sensitivity of the assay. Therefore, it is another object of the present invention to provide a simple, fast, and effective means to assay cytokinin concentrations in a sample.

The applicant has also devised an application for the modified production of *ckx1* in plants. Cytokinins are associated with several types of plant pathogenesis, including the formation of nematode feeder cells, and

fungus invasion of plant tissues. Thus, the pathogen-exposure-regulated production of *ckx1* can modify the efficacy of pathogenesis through cytokinin-utilizing mechanisms such as that utilized by the root-knot
5 nematode, *Meloidogyne spp.* (Bird, et al., 1980), or fungal species such as *Ustilago maydis*. Thus, it is an object of the present invention to provide a method of moderating cytokinin-mediated pathogenesis by transforming a plant with a *ckx1* producing DNA construct.

10 The following examples illustrate the principles and advantages of the invention.

EXAMPLES

Example 1: Isolation of *ckx1* and characterization of its 15 encoding sequence

Maize kernels were chosen as the raw material for purification because of the relatively high concentrations of cytokinin oxidase present about a week after pollination. Using the procedure set forth below, approximately 1.66 μ g protein per kg maize yield may be
20 obtained. Field grown maize (Pioneer 3180 or 3379) was hand pollinated, and immature ears were harvested between 5 and 8 days later (Dietrich, 1995). Kernels were harvested immediately, and frozen at -80°C until
25 extraction. After being powdered in liquid nitrogen, the kernels were blended in 1 kg lots with 1700 ml of Buffer A (50 mM Tris, 5 mM EDTA, ascorbic acid 0.4% w/v; 10 mM β -mercaptoethanol, pH 8.5). Acid washed PVPP (200 g wet weight, equilibrated w/ Buffer A) was stirred in
30 immediately. The slurry was filtered through Miracloth and centrifuged at 23,500 x g for 15 minutes to remove debris. Polyethyleneimine solution (5% v/v, pH 8.5) was added dropwise to the centrifuged supernatant, to a final concentration of 0.05%. After recentrifugation at 23,500

x g for 10 minutes, the supernatant was filtered through a 600 g pad of PVPP (prepared as above). Ammonium sulfate fractionation was performed, and the protein precipitating between 40% and 65% saturation was
5 collected by centrifugation and dissolved in a minimum volume of Buffer B (10 mM Tris, 1 mM EDTA, 1 mM β -mercaptoethanol, pH 8.5). Insoluble material was removed by centrifugation at 35,000 x g for 20 minutes. At this point, glycerol may be added to the supernatant to 10%
10 v/v, allowing the protein to be stored at -80°C indefinitely without loss of activity.

After dialyzing the supernatant from the ammonium sulfate fractionation against Buffer B, the fraction was applied to a DEAE-cellulose column (Whatman DE-52, 500
15 ml, available from the Whatman Group, Clifton, New Jersey) at the rate of 10 ml/minute. After washing w/ buffer B, the column was eluted with a linearly increasing concentration of KCl in Buffer B, to 200 mM over 600 ml. Protein content was measured using the
20 Bradford dye binding assay (Bradford, 1976). Fractions were analyzed for oxidase activity as described below.

Two assays were used to screen purification steps for cytokinin oxidase activity. The first was the Schiff base formation assay measuring the production of
25 dimethylallylaldehyde from iP, as described by Liberos-Minotta (1995), which was used up through the DEAE column step. A second assay, developed by the applicant, was used in the remaining purification steps. In this assay, the transfer of reducing equivalents from
30 isopentenyladenine to dichlorophenolindophenol (DCPIP), catalyzed by *ckx1*, allows the observance of reactivity by measuring absorbance change at 590 nm. In a final volume of 250 μ l, the assay contains: 100 mM Phosphate buffer, pH 7.0; 1.0 mM EDTA; 0.05 mM DCPIP; 0.1 mM iP; 100 μ g/ml
35 BSA; and the sample tested. After the addition of the enzyme, absorbance change is read at 590 nm for 10 minutes.

After purification on the DEAE column, the major pooled active material was dialyzed against Buffer C (20 mM Tris, 0.5 M NaCl, 1.0 mM CaCl₂, pH 7.4), and applied to a concanavalin A agarose column (100 ml, from Sigma Aldrich, St. Louis, Missouri) and washed w/ Buffer C (270 ml). Glycosylated proteins were eluted with a step gradient of buffer C containing α -D-methylmannoside to 1 M over 400 ml. The relatively long retention time when eluted under these conditions indicates that the glycosylated form of *ckx1* was isolated. Active fractions from the lectin-affinity chromatography were then dialyzed against Buffer D (10 mM Tris, 1 mM EDTA, pH 8.5) and applied to a high resolution anion exchange column (FPLC MonoQ, 1 ml, from Amersham Pharmacia Biotech, Ltd., San Francisco, California), and eluted with a linear gradient of KCl to 0.12 M over 24 minutes at 1 ml/minute. The active fractions from the ion exchange column were then concentrated, dialyzed against Buffer B, brought to 1.5 M ammonium sulphate and applied to a hydrophobic interaction column (FPLC phenylsuperose, 1 ml, Pharmacia) equilibrated in Buffer B containing 0.6 ammonium sulfate. After washing with 0.6 M ammonium sulfate for 25 minutes, the concentration of ammonium sulfate was reduced successively to 0.45 M over 15 minutes and then to zero over 60 minutes.

Native gel electrophoresis was performed as illustrated in Ornstein (1964) and Davis (1964). Gels were then stained for cytokinin oxidase activity by the DCPIP procedure described above. Enzyme activity was revealed as a transparent band against a blue background. Denaturing SDS polyacrylamide gel electrophoresis was then carried out as illustrated in Laemmli (1970). When testing fractions for homogeneity, the gel was stained as described by Møller (1995). At the final purification step, the enzyme was stained with Coomassie Blue R250. The purified protein was analyzed by tryptic digestion, HPLC separation of digest, and Edman degradation

sequencing of the tryptic polypeptides. Several polypeptide sequences were obtained from this analysis, including SEQ. ID NOS. 4 and 5. From these sequences, reverse translation primer probes, SEQ. ID NOS. 6, 7, 8, and 9, were devised, with inosine substituted at highly degenerative positions. Primers SEQ. ID NOS. 6 and 9 were then combined with maize genomic DNA, and hot-start touchdown PCR was performed (Ault, 1994) for 40 cycles. PCR products were separated on agarose gel, and an approximately 440 bp fragment was chosen to use as a hybridization probe. The identity of the fragment was confirmed by showing that it could be amplified by PCR with the nested internal primers SEQ. ID NOS. 7 and 8. The fragment amplified by the primers SEQ. ID NOS. 6 and 9 was then ligated into linearized pCRII DNA and transformed into *E. coli* (INVαF', Invitrogen Corp., Carlsbad, California). After cloning and reisolation of DNA, plasmid inserts were sequenced using the Prism dideoxy terminator method of Applied Biosystems, Foster City, CA, to verify that the sequenced tryptic digest polypeptides were encoded by the fragment.

Once the large fragment had been verified, it was labeled with ^{32}P by primer extension using the Klenow fragment of DNA polymerase and primers SEQ. ID NOS. 6 and 9. Maize genomic library phage (in λ-FIXII, from Stratagene, La Jolla, California) were diluted in SM Buffer, and appropriate numbers added to freshly prepared *E. coli* (XL1-Blue MRA (P2), Stratagene) in 10 mM MgSO_4 and incubated at 37°C for 15 minutes. NZY top agar at 48°C was added and the mixture plated onto NZY agar plates. After incubation for approximately 8 hours at 37°C, plates were cooled to 4°C for 2 hours and phage were adsorbed onto sheets of Hybond N membrane (Amersham Pharmacia Biotech, San Francisco, California). Membranes were air-dried for 10 minutes, and incubated successively with 0.5 M NaOH plus 1.5 M NaCl, 500 ml, 5 minutes; 0.5 Tris-Cl pH 8.0 plus 1.5 M NaCl, 500 ml, 5 minutes; and 2 x SSC, 500 ml,

5 minutes. They were blotted dry and baked at 80°C until dry (approximately 15 minutes). Membranes were pre-hybridized at 45°C for less than one hour in 50% formamide, 5 x SSPE, 2 x Denhardt's solution, 0.2% SDS, 100-200 µg/ml denatured herring sperm or calf thymus DNA (Maniatis, 1990).

The labeled DNA fragment was then denatured at 100°C for 5 minutes, added to the pre-hybridization solution, and hybridized for 16 hours at 45°C. For the primary screen, phage were plated at a density of 500 pfu/cm² and membranes were washed at high stringency. For subsequent plaque purification, candidate phage were plated at a density of 70 pfu/cm² and 2 pfu/cm² and membranes were washed at medium stringency. After three rounds of purification, subfragments of the insert were removed from positive phage DNA by restriction and subcloned into pBluescript (Stratagene) for characterization by restriction digestion and sequence analysis. Two overlapping plasmid subclones, pROM2 (a HindIII insert) and pROM3 (an Xho-BamHI insert) each contained part of the gene for *ckx1*. These overlapping sections have been fused into the plasmid clone pROM10. The plasmids pROM2, pROM3, and pROM10 have been deposited with the American Type Culture Collection as ATCC Nos. 209573, 209572, and 209571, respectively. The sequence of the cloned DNA in pROM2 and pROM3 provided the genomic sequence of *ckx1*, SEQ. ID NO. 2, which was verified by the inclusion of sequences coding for the tryptic digest fragments obtained above.

The location of the introns in the *ckx1* gene, and the coding sequence for *ckx1* (SEQ. ID NO. 3) was verified by use of the reverse transcriptase polymerase chain reaction (RT-PCR) according to the following procedure.

Total RNA (2-4 µg, DNAase I-treated) from kernels harvested five days after pollination (5 DAP) was primed for RT-PCR using oligonucleotides bracketing the intron

sites. Primers 2031f (*ckx1* genomic sequence 2031-2050) and XBH1 (reverse complement of *ckx1* genomic sequence 2553-2570) covered the first intron site. Primers 3160f (*ckx1* genomic sequence 3160-3179) and 3484r (reverse complement of *ckx1* genomic sequence 3465-3484) covered the second intron site. Reverse transcription was at 50°C for 50 min. with 200U Superscript II (Gibco-BRL) in 20 µL total volume with 25 mM Tris-Cl, pH 8.3, 37.5 mM KCl, 1.5 mM MgCl₂, 0.5 mM dNTPs, 5mM dithiothreitol, 40U RNAasin (Promega, Madison, Wisconsin). PCR was performed with 4-10% of the RT reaction product as template and 1U Taq polymerase in 1X PCR buffer (Roche Diagnostics, Basel, Switzerland), 200 µM dNTPs, and 0.5 µM each primer. Reaction conditions were: an initial denaturation at 95°C for four minutes followed by thirty-five cycles of 95° denaturation for one minute, 60° annealing for one minute, and 72° extension for one minute. A final four minute extension was carried out at 72°. PCR products were resolved on 1.5% agarose gels. PCR products were excised from gels and sequenced to determine splice site junctions.

RT-PCR of maize kernel RNA (5 days after pollination) with primers designed to span the first and second intron locations demonstrated PCR product sizes consistent with splicing out of these introns in the mature oxidase mRNA. The primers bracketing the first intron should give a 539 bp product if the intron is present and a 127 bp product if it has been spliced out. Likewise, the primers bracketing the second intron should give a 324 bp product if the second intron is present and a 232 bp product if it has been spliced out. As shown in

Figure 2, the PCR products were 127 bp and 232 bp respectively, indicating that the introns had indeed been spliced out. Sequence analysis of the fragments confirmed that splicing had occurred as predicted.

5 The identity of the *ckx1* protein and gene were further verified by the following immunological technique.

Polyclonal antibodies were raised in goats to the peptide produced by expression of a *ckx1* gene fragment in
10 *E. coli*. This avoided the presentation of a glycosylated surface when raising antibodies to the gene product and the problems encountered by Burch, et al., when raising antibodies to naturally occurring *ckx1*. Goat antibodies from immunized and unimmunized animals were partially
15 purified by sodium sulfate precipitation (Williams, et al., 1967). Affinity columns were prepared by coupling these purified antibodies (2 mg) to Aminolink Plus gels (1 mL, Pierce) at pH 10, following the manufacturer's protocol. Activity depletion assays were performed by
20 adding 0.2 mL (27 μ g) of a maize ConA-fractionated oxidase preparation plus 0.8 mL phosphate buffered saline (PBS) to each column. The columns were capped and incubated for one hour at room temperature. Eluate was collected and assayed for cytokinin oxidase activity.

25 Antibodies to *ckx1* recognize the major maize cytokinin oxidase enzyme. A column containing immobilized anti-*ckx1*-fragment antibody was able to deplete cytokinin oxidase activity from a ConA-fractionated maize extract. A control column of
30 unimmunized goat antibodies was not able to do so.

Example 2: Expression of *ckx1* in *Pichia pastoris*

ckx1 protein may be produced in bulk by the following procedure for use in applications such as the cytokinin assay of Example 3, or application to plant materials.

Expression of *ckx1* in *Pichia pastoris* was carried out in four stages:

Step 1. Removal of the introns from *ckx1*

Step 2. Removal of the maize promoter and construction of the appropriate expression cassette using the intron-less construct

Step 3. Transformation of the final construct into *Pichia* and

Step 4. Expression of *ckx1* in *Pichia*

Removal of the right-most intron was accomplished by splicing by overlap extension (Horton et al., 1989) and for the left-most intron by ligation of suitable restriction fragments. The resulting intronless cassette was inserted into the *Pichia* expression vector pPICZ-A to give the expression construct pROM24 (FIG. 9). This construct was introduced into the requisite *Pichia* host and grown in the presence of methanol to induce *ckx1* expression. Appropriate control *Pichia* lines (containing the vector alone or a recombinant expressing human serum albumin) were grown in parallel.

No cytokinin oxidase activity was observed in *Pichia* cell lysates containing *ckx1* or the controls at any time during the growth curve. However, the *Pichia* line harboring *ckx1* expressed and secreted high levels of cytokinin oxidase activity into the growth medium. No activity was observed in control supernatants. This provided further verification that *ckx1* does indeed encode a cytokinin oxidase.

Step 1. Intron removal: The second intron (SEQ. ID NO. 2 residues 3219-3312) was removed by splicing by overlap extension with selected *ckx1* restriction fragments as templates to limit artifactual priming. The following table lists the primers and templates used.

Intron	Left Primer	Right primer	Template DNA
amplification #1	TGGGAATTCATGGGGAGA TGGTGACGTGCTC (SEQ. ID NO. 11)	GCCGTCCCACATGGATTGT TGAGGGGGTAGAC (SEQ. ID NO. 12)	pROM2 NcoI/PinA1 (700 bp) fragment
amplification #2	CTCAACAAATCCATGTGGG ACGACGGCATGTCGGCGG (SEQ. ID NO. 13)	GCGGTCTAGATCTAACTAAA ACATGCATGGGCTATCATC (SEQ. ID NO. 14)	pROM2 390 bp PinA1 + Vsp1
amplification #3	ATGGGAATTCATGGGGAG ATGGTGACGTGCTC (SEQ. ID NO. 15)	GCGGTCTAGATCTAACTAAA ACATGCATGGGCTATCATC (SEQ. ID NO. 16)	Products from amplifications #1 and # 2

PCR products from reactions #1 and #2 were gel-purified and used in the final PCR step. The final product from reaction #3 was cloned and sequenced and a *PflM1/Xba1* subfragment was substituted for the intron-containing *PflM1/Xba1* subfragment of pROM7. The construct was designated pROM19. The first intron (SEQ. ID NO. 2 residues 2113-2524) was then removed from pROM19 by replacement of the DNA between the restriction sites *PinA1* and *Nco1* with a linker constructed from the oligonucleotides CCGGTTTTGGTACCGGT (SEQ. ID NO. 17) and CATGACCGGTACCAAAA (SEQ. ID NO. 18). The product was designated pROM20. Extraneous linker-associated bases were removed by digestion with *PinA1* followed by re-ligation. The product, designated pROM22 (FIG. 8), contained the three fused *ckx1* exons and the maize *ckx1* promoter.

Step 2. The *Pichia* expression cassette: The maize promoter was removed by partial digestion of pROM22 (FIG. 8) with *AatII*, filling in the sticky ends with T4 DNA polymerase, and redigestion with *BglII*. The exon fusion

(containing *ckx1* and including its putative signal peptide) was ligated into the *Pml1/BsmB1* restriction sites of pPICZ-A (Easy-Select *Pichia* Expression Kit version B, Invitrogen Corp.). The resulting plasmid was designated pROM24 (FIG. 9).

Step 3. Transformation into *Pichia* strain X33 as described in the Invitrogen protocol: The plasmid pROM24 (FIG. 9) (10 μ g) was digested with *Dra1* and electroporated into competent X33 cells in a 2 mM cuvette at 1.75 kV (GenePulser, Bio-Rad Laboratories, Hercules, California). Selection on YPDS with 100 μ g/mL zeocin resulted in many colonies. One (PP*ckx1*) was selected for expression studies.

Step 4. Expression of the oxidase: The transformant PP*ckx1* was inoculated into BMGY medium (50 mL) and grown overnight. Cells were pelleted, resuspended in BMMY (containing 0.5% v/v methanol), diluted to an $A_{600}=1$ and grown at 30°C with vigorous shaking. Additional methanol was added to 0.5% v/v at 24, 48 and 72 hours post-inoculation. Samples were harvested for assay of cytokinin oxidase activity in cell lysates or in culture supernatants. *Pichia* strains X33 (WT, no insert) and GS115, (secreted human serum albumin insert) served as controls.

Example 3: Use of Recombinant Cytokinin Oxidase in a Rapid Assay Method for Cytokinin

Cytokinins were measured by mixing 100 μ L of a buffer mixture containing phosphate buffer (250 mM, pH 7.0), EDTA (2.5 mM) and DCPIP (0.125 mM), and an excess of recombinant cytokinin oxidase with solutions (150 μ L) of zeatin at various concentrations. The net change in absorbance was measured at 590 nm.

Figure 3 illustrates the change in absorbance when the assay is used to measure the cytokinin zeatin. The method is capable of measuring as little as 2 nmol zeatin but, the major advantage of the assay over the prior art is its rapidity. Assays can be preformed in as little as five minutes, significantly faster than radioimmunoassays (MacDonald and Morris, 1985). Further, the method can be integrated into cytokinin production systems by coupling the *ckx1* gene to such cytokinin producing genes as *ipt* or *tzs*, in order to assay cytokinin production in vitro.

Example 4: Unregulated and Regulated Expression of *ckx1* Constitutively and in the Roots of *Nicotiana tabacum*

The following procedure, which produces tobacco plants altered to express *ckx1* constitutively and in their roots, is a slight modification of the standard protocols described in Draper, et al., 1988.

Nicotiana tabacum cultivar Xanthi is a standard tobacco line. Disarmed *Agrobacterium tumefaciens* strains such as LBA4404 (Hoekema, et al., 1985) are used. Murashige and Skoog salts, phytagar, sucrose, etc. are reagent or tissue-culture grade.

Three separate constructs were made with the *ckx1* coding sequence (SEQ. ID NO. 3) to effect three different patterns of *ckx1* expression in transformed tobacco plants. Constructs were based on the BIN19 plasmid primary vector (which includes an *Agrobacterium* compatible replication origin and kanamycin selection markers, Bevan, et al., 1984). The following constructs were made:

CaMV-ckx1-nos: The cauliflower mosaic virus promoter with a *nos* enhancer (U.S. Patent No. 5,530,196), are present in pBI121 (FIG. 5) (available from Clontech, Palo

Alto, California). The β -glucuronidase gene of pBI121 was excised with a *Bam*HI/*Eco*ICrI digest. The coding sequence of *ckx1* (SEQ. ID NO. 3) was obtained by a *Bgl*II digest of pROM26 (FIG. 10) (pROM24 (FIG. 9) altered by site-directed mutagenesis to contain another *Bgl*II and an *Xho*I restriction site). The final construct pROM30 (FIG. 13), which induces strong constitutive expression of *ckx1*, was created by digesting the altered pBI121 with *Bam*HI and ligating in the *ckx1* coding sequence.

10 *CaMV-tet-ckx1-ocs*: The *ckx1* coding region of pROM26 (FIG. 10) was isolated by *Bgl*II digestion and ligated into the *Bam*HI site of pUCA7-TX (Gätz, et al., 1992) to form pROM32 (FIG. 14). The tetracycline-regulated operator element (U.S. Patent No. 5,464,758) from pUCA7-TX and the inserted coding region were excised from
15 pROM32 (FIG. 14) by *Pvu*II digestion. The final construct pROM29 (FIG. 12), was produced by ligating the excerpt into the *Sal*I site of pJL7 (FIG. 4) (a BIN19 type plasmid). When this construct is introduced into tobacco
20 previously transformed to express the tet repressor protein, no *ckx1* activity will be expressed until repression is relieved by addition of tetracycline. This construct may be of particular use in host organisms where strong constitutive expression of *ckx1* results in
25 abnormal growth patterns.

RB7-ckx1-nos: The tobacco RB7 root specific promotor (U.S. Patent No. 5,750,386), was obtained by the following method. A fragment containing the promoter was PCR-amplified from tobacco genomic DNA using
30 GACACCATTCGAAGCATACCCC (SEQ. ID NO. 19) and GTTCTCACTAGAAAAATGCCCC (SEQ. ID NO. 20) as primers. This 1400 bp product was ligated into the pCRII plasmid

(Invitrogen) to produce pROM8 (FIG. 6). The *HindIII-EcoRI* region of the insert, containing the nematode-specific portion of the promoter, was then excised and ligated into the *HindIII-EcoRI* site of pBluescriptII KS+ (Stratagene) to produce pROM9 (FIG. 7). The *EcoRI-NsiI* fragment of pROM24 (FIG. 9), containing the *ckx1* coding sequence, was excised and ligated into the *EcoRI-PstI* site of pROM9, to make pROM28 (FIG. 11). The final construct pROM43 (FIG. 15), which induces expression of *ckx1* in roots when the transformed plants' roots are attacked by nematodes, was produced by ligating a *HindIII-SacI* fragment of pROM28 into the *HindIII-SacI* site of pBI121 (FIG. 5).

	Media Component	MSS	PC	SI	MSSK
15	MS Salts (g/l)	4.3	4.3	4.3	4.3
	Sucrose (g/l)	30.0	30.0	30.0	30.0
	Phytagar (g/l)	7.5	5.0	5.0	7.5
	NAA (mg/l)	0	1.0	1.0	0
	BAP (mg/l)	0	0.1	0.1	0
20	Timetin (mg/l)	0	0	200	200
	Kanamycin (mg/l)	0	0	50.0	50.0
	pH	5.7	5.7	5.7	5.7

Nicotiana was continuously maintained by axenic shoot tip culture on MSS and sub-cultured at 4 week intervals.

The three binary plasmid constructs described above were electroporated into the disarmed *A. tumefaciens* host and transformants were grown under suitable selection (An, et al. 1985). Late-log phase cultures were used for transformation.

Young axenic tobacco leaves (3 to 4 weeks after tip culture) were dissected into 4 to 6 segments, excluding

the largest vasculature. Segments were cultured on PC, abaxial side up, for 48 hours. The leaf pieces were then soaked in transformed *A. tumefaciens* culture diluted with water (1:1), for 1 hour. Pieces were then placed on the original PC medium for 48 hours. The leaves were then washed with water thoroughly and placed on SI medium and removed to fresh SI medium every 7 to 10 days. Although no adverse developmental effects were observed with *Nicotiana* transformants, the use of a non-substrate cytokinin such as benzylaminopurine, or tetracycline repression, may be needed for the culture of some host plants. Shoots were removed onto MSSK media when 1 cm long. Successive tip culture was carried out for 2 to 3 transfers, after which the transgenic plants were maintained on MSS media.

In light of the detailed description of the invention and the examples presented above, it can be appreciated that the several objects of the invention are achieved. The explanations and illustrations presented herein are intended to acquaint others skilled in the art with the invention, its principles, and its practical application. Those skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use. Accordingly, the specific embodiments of the present invention as set forth are not intended as being exhaustive or limiting of the invention.

BIBLIOGRAPHY

- An, G., et al., 1985: "New cloning vehicles for transformation of higher plants," EMBO J. 4:277-84
- Ault, G., 1994: "Type-specific amplification of viral DNA using touchdown and hot start PCR," J. Virol. Meth. 46:145-56.
- Bechtold, N., et al., 1993: "In planta *Agrobacterium* mediated gene transfer by infiltration of adult *Arabidopsis thaliana* plants," CR Acad. Sci. Paris Sciences del la vie/ life sciences 316:1194-99.
- Bevan, M., 1984: "Binary *Agrobacterium* vectors for plant transformation," Nuc. Acids Rsrch. 12:8711-21.
- Bird, A.F., et al., 1980: "The involvement of cytokinins in a host-parasite relationship between the tomato (*Lycopersicon esculentum*) and a nematode (*Meloidogyne javanica*)," Parasitology 80:497-505.
- Bradford, M., 1976: "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," Analytical Biochem. 72:248-54.
- Brownlee, B.G., et al., 1975: "3-Methyl-2-butenal: An Enzymatic Degradation Product of the Cytokinin, N⁶-(Δ^2 -isopentenyl)adenine," Can. J. Biochem. 53:37-41.
- Burch, L.R., et al., 1992: "Cytokinin Oxidase and the Degradative Metabolism of Cytokinins," in Kaminek, et al. Physiology and Biochemistry of Cytokinins in Plants. pp. 229-32, STP Academic Publishing, The Hague, Netherlands.
- Chen, H., et al., 1996: "Novel methods of generating specific oligonucleotide inhibitors of viral polymerases." Methods in Enzymology 275:503-20.
- Davis, B., 1964: "Disk Electrophoresis II. Method and application to human serum proteins," Ann. N.Y. Acad. Sci. 121:404.

Dietrich, J.T., et al., 1995: "Changes in cytokinins and cytokinin oxidase activity in developing maize kernels and the effects of exogenous cytokinin on kernel development," Plant Physiol. Biochem. 33:327-36.

- 5 Draper, J., et al., 1988: Plant Genetic Transformation and Expression: A Laboratory Manual. Blackwell Scientific Publications.

Gätz, C., et al., 1992: "Stringent repression and homogenous de-repression by tetracycline of a modified
10 *CaMV* 35 *S* promoter in intact tobacco plants." Plant J. 2(3):397-404.

Hare, P.D., et al., 1994: "Cytokinin oxidase: Biochemical features and physiological significance," Physiologia Plantarum 91:128-35.

- 15 Hoekema, A., et al., 1985: "Non-oncogenic plant vectors for use in *Agrobacterium* binary systems," Plant. Mol. Biol. 5:85-89.

Horton, R.M., et al., 1989: "Engineering hybrid genes without the use of restriction enzymes: gene
20 splicing by overlap extension," Gene 77:61-8.

Kozziel, et al., 1993: "Field performance of elite transgenic maize plants expressing an insecticidal protein from *Bacillus thuringiensis*," Bio/Technology 11:194

- 25 Laemmli, U.K., 1970: "Cleavage of structural proteins during the assembly of the head of bacteriophage T4," Nature 227:680-685.

Liberos-Minotta, C., et al., 1995: "A colorimetric Assay for Cytokinin Oxidase," Analytical Biochem.
30 231:339-341.

MacDonald, E.M.S., et al., 1985: "Isolation of cytokinins by immunoaffinity chromatography and isolation by HPLC-radioimmunoassay," Methods in Enzymology 110: 347.

- 35 Maniatis, T., et al., 1990: Molecular Cloning. A Laboratory Manual 2nd Ed. Cold Spring Harbor Laboratory Press.

- Møller, H.J., et al., 1995: "Improved method for Silver Staining of Glycoproteins in Thin Sodium Dodecyl Sulfate Polyacrylamide Gels," Analytical Biochem. 226:371-74.
- 5 Odell, et al., 1985: "Identification of DNA sequences required for activity of the cauliflower mosaic virus 35S promoter," Nature 313:810.
- Ooms, G., et al., 1987: "Genetic transformation in two potato cultivars with T-DNA from disarmed
- 10 *Agrobacterium*," Theor. Appl. Genet. 73:744-50.
- Ornstein, L., 1964: "Disk Electrophoresis I. Background and theory," Ann. N.Y. Acad. Sci. 121:321.
- Potrykus, 1991: "Gene transfer to plants: assessment of published approaches and results," Annu. Rev. Plant
- 15 Physiol., Plant Mol. Biol., 42:205.
- Singer, B.S., et al., 1996: "Libraries for genomic SELEX," Nucleic Acids Resrch. 25:781-86.
- Skory, C.D., et al., 1996: "Expression and secretion of the *Candida wickerhamii* extracellular beta-glucosidase
- 20 gene, bgls, in *Saccharomyces cerevisiae*," Current Genetics 30:417-422.
- Smith, C.T.S., et al., 1988: "Antisense RNA inhibition of polygalacturonase gene expression in transgenic tomatoes," Nature 334:724-26.
- 25 Su, W., et al., 1996: "Identification in vitro of a post-translational regulatory site in the hinge 1 region of *Arabidopsis* nitrate reductase," Plant Cell 8:519-27.
- Van der Krol, A.R., et al., 1990: "Inhibition of flower pigmentation by antisense CHS genes: promoter and
- 30 minimal sequence requirements for the antisense effect," Plant Molec. Biol. 14:457-66.
- Williams, C. A., et al., 1967: Methods in Immunology and Immunohistochemistry I p. 319.

WE CLAIM AS OUR INVENTION:

1. A substantially purified protein which exhibits cytokinin oxidizing activity, selected from the group consisting of:

- (a) SEQ. ID NO. 1,
- 5 (b) a protein having an amino acid sequence which includes the amino acid sequence of SEQ. ID NO. 1,
- (c) a protein having an amino acid sequence which includes a portion of the amino acid sequence of SEQ. ID NO. 1, the included portion being at least about 20 amino
- 10 acid residues in length and conferring the cytokinin oxidizing activity on the protein, and
- (d) a protein including an amino acid sequence with at least about 65% sequence identity to SEQ. ID NO. 1, the remainder of amino acid residues being conservatively substituted.

2. The protein of claim 1 wherein the protein is purified.

3. The protein of claim 1 which is SEQ. ID NO. 1.

4. The protein of claim 1 produced by a host cell transformed with a vector containing a nucleic acid polymer which encodes the protein of claim 1.

5. A substantially isolated nucleic acid polymer encoding a protein of claim 1.

6. The substantially isolated nucleic acid polymer of claim 5 which encodes SEQ. ID NO. 1.

7. A substantially isolated nucleic acid polymer which encodes a protein which exhibits cytokinin oxidizing activity, wherein the nucleic acid polymer is selected from the group consisting of:

- 5 (a) SEQ. ID NO. 2,

- (b) SEQ. ID NO. 3,
- (c) a nucleic acid polymer with a sequence described by SEQ. ID NO. 10,
- (d) a nucleic acid polymer whose sequence contains
5 a sequence selected from the group consisting of SEQ. ID NO. 2, SEQ. ID NO. 3, or a nucleic acid polymer with a sequence described by SEQ. ID NO. 10.
- (e) a nucleic acid polymer which contains at least one 60 base pair portion, which encodes an amino acid
10 sequence which confers cytokinin oxidizing activity upon the encoded protein, of a nucleotide sequence selected from the group consisting of SEQ. ID NO. 2, SEQ. ID NO. 3, and a nucleic acid polymer with a sequence described by SEQ. ID NO. 10,
- 15 (f) a nucleic acid polymer which encodes a protein including an amino acid sequence with at least about 65% sequence identity to SEQ. ID NO. 1, the remainder of amino acid residues being conservatively substituted,
- (g) a nucleic acid polymer which hybridizes to a
20 nucleotide sequence selected from the group consisting of SEQ. ID NO. 2, SEQ. ID NO. 3, and a nucleic acid polymer with a sequence described by SEQ. ID NO. 10, under a wash stringency equivalent to 0.5X to 2X SSC buffer, 0.1% SDS, at 55-65°C, and
- 25 (h) a nucleic acid polymer having a nucleotide sequence complementary to any of the nucleic acid sequences (a) - (g).

8. The substantially isolated nucleic acid polymer of claim 7 wherein the polymer contains a sequence described by SEQ. ID NO. 10 or a sequence complementary to a sequence described by SEQ. ID NO. 10.

9. The substantially isolated nucleic acid polymer of claim 7 wherein the polymer is SEQ. ID No. 2 or its complementary sequence.

10. The substantially isolated nucleic acid polymer of claim 7 wherein the polymer is SEQ. ID No. 3 or its complementary sequence.

11. A host cell transformed with a vector containing a deoxyribonucleic acid polymer which encodes the protein of claim 1.

12. The host cell of claim 11, wherein the host cell is a plant cell.

13. The host cell of claim 12, wherein the host plant cell is selected from the group consisting of:

- (a) *Nicotiana tabacum*,
- (b) *Arabidopsis thaliana*,
- 5 (c) *Zea mays*
- (d) *Brassica spp*
- (e) *Oryza sativa*

14. The host cell of claim 11 wherein the host cell is selected from the group consisting of:

- (a) *Pichia pastoris*
- (b) *Escherichia coli*

15. A plant regenerated from the host plant cell in claim 12.

16. A plant product from the regenerated plant of claim 15.

17. The plant product of claim 16, wherein said plant product is selected from the group consisting of seeds, leaves, stem cultures, rhizomes, and bulbs.

18. A method for producing the protein of claim 1 in a host cell, essentially comprising

(a) constructing a vector containing DNA encoding the protein of claim 1 and an expression regulatory sequence operational in the host cell;

(b) transfecting a host cell suitable for protein
5 production with the vector; and

(c) expressing the protein in the host cell.

19. The method of claim 18 wherein the vector is selected from the group consisting of:

(a) a plasmid comprised of DNA,

(b) *Agrobacterium tumefaciens*

20. The method of claim 18, wherein the host cell is selected from the group consisting of:

(a) *Pichia pastoris*

(b) *Escherichia coli*

21. The method of claim 18 wherein the host cell secretes said protein into a culture medium, and wherein the method further comprises purifying said protein from the culture medium.

22. The method of claim 18 further comprising the step of reconstituting the host cell into an organism.

23. The method of claim 18, wherein the host cell is a plant cell.

24. The method of claim 23, wherein the host plant cell is selected from the group consisting of:

- (a) *Nicotiana tabacum*,
- (b) *Arabidopsis thaliana*,
- 5 (c) *Zea mays*
- (d) *Brassica spp*
- (e) *Oryza sativa*

25. A method of moderating cytokinin-associated pathogenesis in a plant comprising transforming a plant cell with a nucleic acid polymer construct which contains:

- 5 (a) a nucleic acid polymer encoding the protein of claim 1, and
 - (b) an expression regulatory sequence operational in the host plant; and
- regenerating a plant from the transformed plant cell.

26. A method as set forth in claim 25 wherein the expression regulatory sequence is selected from the group consisting of constitutive promoters, inducible promoters, repressors, and enhancers.

27. A method of detecting cytokinin concentrations in a sample essentially comprising:

- (a) adding to a buffered sample known amounts of dichlorophenolindophenol and an excess IU activity
- 5 producing amount of the protein of claim 1;
- (b) measuring the net change in absorbance of light at 590 nm; and
- (c) comparing this net absorbance to a standard curve generated from known concentrations of cytokinin.





FIG. 1a

 N^6 -(Δ^2 -isopentenyl)adenine

3-methyl-2-butenal

FIG. 2A
VERIFICATION OF *ckx1* GENE INTRON
LOCATIONS BY RT-PCR
1 2 3 4 5 6



FIG. 2B
VERIFICATION OF *ckx1* GENE INTRON
LOCATIONS BY RT-PCR
1 2 3 4 5 6 7








FIG.3

USE OF RECOMBINANT CKX1 TO ASSAY ZEATIN LEVELS










FIG. 11




FIG. 12




FIG. 13






FIG.14



8 / 8

FIG.15



SEQUENCE LISTING

<110> Morris Ph.D., Roy O.

<120> A CYTOKININ OXIDASE

<130> UMO 1491

<140>

<141>

<150> 06/054,268

<151> 1997-07-30

<160> 20

<170> PatentIn Ver. 2.0

<210> 1

<211> 534

<212> PRT

<213> Zea mays

<400> 1

Met Ala Val Val Tyr Tyr Leu Leu Leu Ala Gly Leu Ile Ala Cys Ser
1 5 10 15His Ala Leu Ala Ala Gly Thr Pro Ala Leu Gly Asp Arg Gly Arg
20 25 30

5	Pro Trp Pro Ala Ser Leu Ala Ala Leu Ala Leu Asp Gly Lys Leu Arg 35 40 45
	Thr Asp Ser Asn Ala Thr Ala Ala Ser Thr Asp Phe Gly Asn Ile 50 55 60
	Thr Ser Ala Leu Pro Ala Ala Val Leu Tyr Pro Ser Ser Thr Gly Asp 65 70 75 80
	Leu Val Ala Leu Leu Ser Ala Ala Asn Ser Thr Pro Gly Trp Pro Tyr 85 90 95
10	Thr Ile Ala Phe Arg Gly Arg Gly His Ser Leu Met Gly Gln Ala Phe 100 105 110
	Ala Pro Gly Gly Val Val Val Asn Met Ala Ser Leu Gly Asp Ala Ala 115 120 125
15	Ala Pro Pro Gly Ile Asn Val Ser Ala Asp Gly Arg Tyr Val Asp Ala 130 135 140
	Gly Gly Glu Gln Val Trp Ile Asp Val Leu Arg Ala Ser Leu Ala Arg 145 150 155 160
	Gly Val Ala Pro Arg Ser Trp Asn Asp Tyr Leu Tyr Leu Thr Val Gly 165 170 175
20	Gly Thr Leu Ser Asn Ala Gly Ile Ser Gly Gln Ala Phe Arg His Gly 180 185 190
	Pro Gln Ile Ser Asn Val Leu Glu Met Asp Val Ile Thr Gly His Gly 195 200 205

Glu Met Val Thr Cys Ser Lys Gln Leu Asn Ala Asp Leu Phe Asp Ala
 210 215 220
 Val Leu Gly Gly Leu Gly Gln Phe Gly Val Ile Thr Arg Ala Arg Ile
 225 230 235 240
 Ala Val Glu Pro Ala Pro Ala Arg Ala Arg Trp Val Arg Phe Val Tyr
 245 250 255
 Thr Asp Phe Ala Ala Phe Ser Ala Asp Gln Glu Arg Leu Thr Ala Pro
 260 265 270
 Arg Pro Gly Gly Gly Ala Ser Phe Gly Pro Met Ser Tyr Val Glu
 275 280 285
 Gly Ser Val Phe Val Asn Gln Ser Leu Ala Thr Asp Leu Ala Asn Thr
 290 295 300
 Gly Phe Phe Thr Asp Ala Asp Val Ala Arg Ile Val Ala Leu Ala Gly
 305 310 315 320
 Glu Arg Asn Ala Thr Thr Val Tyr Ser Ile Glu Ala Thr Leu Asn Tyr
 325 330 335
 Asp Asn Ala Thr Ala Ala Ala Val Asp Gln Glu Leu Ala Ser
 340 345 350

5

10

15

Val Leu Gly Thr Leu Ser Tyr Val Glu Gly Phe Ala Phe Gln Arg Asp
 355 360 365
 Val Ala Tyr Ala Ala Phe Leu Asp Arg Val His Gly Glu Glu Val Ala
 370 375 380
 Leu Asn Lys Leu Gly Leu Trp Arg Val Pro His Pro Trp Leu Asn Met
 385 390 395 400
 Phe Val Pro Arg Ser Arg Ile Ala Asp Phe Asp Arg Gly Val Phe Lys
 405 410 415
 Gly Ile Leu Gln Gly Thr Asp Ile Val Gly Pro Leu Ile Val Tyr Pro
 420 425 430
 Leu Asn Lys Ser Met Trp Asp Asp Gly Met Ser Ala Ala Thr Pro Ser
 435 440 445
 Glu Asp Val Phe Tyr Ala Val Ser Leu Leu Phe Ser Ser Val Ala Pro
 450 455 460
 Asn Asp Leu Ala Arg Leu Gln Glu Gln Asn Arg Arg Ile Leu Arg Phe
 465 470 475 480
 Cys Asp Leu Ala Gly Ile Gln Tyr Lys Thr Tyr Leu Ala Arg His Thr
 485 490 495
 Asp Arg Ser Asp Trp Val Arg His Phe Gly Ala Ala Lys Trp Asn Arg
 500 505 510
 Phe Val Glu Met Lys Asn Lys Tyr Asp Pro Lys Arg Leu Leu Ser Pro
 515 520 525

5

10

15

20

Gly Gln Asp Ile Phe Asn
530

5 <210> 2
<211> 6733
<212> DNA
<213> Zea mays

10 <220>
<221> gene
<222> (1)..(6733)
<223> genomic sequence for a cytokinin oxidase from Zea
mays

15 <220>
<221> CDS
<222> (1497)..(2111)

<220>
<221> CDS
<222> (2524)..(3216)

20 <220>
<221> CDS
<222> (3311)..(3607)

25 <220>
<221> unsure
<222> (5697)

SUBSTITUTE SHEET (rule 26)

<400> 2
ctcgagactc cgacgagagg aggctgcgca tgcttgagtc atatcttggg aaaaaaaact 60
gtaacttaaa gtatgatcta tatatggatt atttggatgg gatgtcattt tcgtatcacc 120
aaccaaaatt acagtttgggt cgtgcgtaga aattctacct actagctgaa acaacgggctg 180
ctatgtataa ctactggtac tggaaaagaat attagtcatt gactcaaaat tagaatgcat 240
gtgtaagtca tgcgtgctaa tttgttctat cagcattcgg cgaattccga agtccgtacg 300
tgttgttcgt ggaggagagg aaaacatcag aaatgacaaa actagacggt gtgtgccttct 360
acactgaatt cctcaacatt tgttttactt ttactagaga atggcatcaa atggaaaacc 420
gctggaaaaa aaacaacaaa acaattggac cccaaaatatg tatacagacg ctactatag 480
ccagccacac tgaagttgac atgcgggcagc tagctagcca ccttctctga aacactaaca 540
tttgtacctt ggtcgtgtaa gtgtagtagt aacgtatgtt gacgcgactt accgaacaaa 600
aataataattg tcccaaatcaa gctaggggacg attgtttgtt tccaaaaatgt tgccatttgc 660
ttaatcaatc ctatattaat tcatgggctgt taagtgaga taaagcgaca agaaatctat 720
atatatgtat ataagatccc gaaggctagc gacatttttg atagcaaaat atgagaagtt 780
tggcagattg ttctggtagc aaatcaata atatggccag aataatcgtg gctagcttga 840
ttaaaccttc atcagcttgg tgtatttttg aagtcgacca accagctggg ggtcgtcgta 900
cgtagtacca aaattacagc ctgcttttctt tcgtcctgtgta cgtaaatgcag tacagctgtc 960

SUBSTITUTE SHEET (rule 26)

5

10

15

20

5
 10
 15
 20

1691
 1739
 1787
 1835
 1883
 1931
 1979
 2027

gac agc aac gcg acg gcg ggc ggc ttc ggc aac atc acg
 Asp Ser Asn Ala Thr Ala Thr Ala Ser Thr Asp Phe Gly Asn Ile Thr
 50 55 60 65
 tgc ggc ctc ccg gcg ggc gtc ctg tac ccg tgc tcc acg ggc gac ctg
 Ser Ala Leu Pro Ala Ala Val Leu Tyr Pro Ser Ser Thr Gly Asp Leu
 70 75 80
 gtg gcg ctg ctg agc gcg ggc aac tcc acc ccg ggc tgg ccc tac acc
 Val Ala Leu Leu Ser Ala Ala Asn Ser Thr Pro Tyr Trp Pro Tyr Thr
 85 90 95
 atc gcg ttc cgc ggc ggc cgc cgc ctc ctg ggc ggc ttc ggc
 Ile Ala Phe Arg Gly Arg Val His Ser Leu Met Gly Gln Ala Phe Ala
 100 105 110
 ccc ggc ggc gtc gtc gtc aac atg gcg tcc ctg ggc ggc ggc ggc
 Pro Gly Gly Val Val Val Asn Met Ala Ser Leu Gly Asp Ala Ala
 115 120 125
 ccg ccg cgc atc aac gtc gtc ggc ggc ggc cgc tac gtc gac ggc ggc
 Pro Pro Arg Ile Asn Val Val Ser Ala Asp Gly Arg Tyr Val Asp Ala Gly
 130 135 140 145
 ggc gag cag gtg tgg atc gac gtc gtc gtc ggc ggc ggc ggc ggc
 Gly Glu Gln Val Trp Ile Asp Val Leu Arg Ala Ser Leu Ala Arg Gly
 150 155 160
 gtg ggc ccg cgc tcc tgg aac gac tac ctc acc gtc ggc ggc
 Val Ala Pro Arg Ser Trp Asn Asp Tyr Leu Tyr Thr Val Gly Gly
 165 170 175

acg ctg tcc aac gca ggc atc agc ggc cag gcg ttc cgc cac ggc cca 2075
 Thr Leu Ser Asn Ala Gly Ile Ser Gly Gln Ala Phe Arg His Gly Pro
 180 185 190

cag ata tct aac gtg ctg gag atg gac gtt atc acc ggtacgtgtg 2121
 Gln Ile Ser Asn Val Leu Glu Met Asp Val Ile Thr
 195 200 205

cacctactac tacttttttcc ctcccttgca caagtgcaca accacaccac agcaagcgag 2181
 caaaagcttg tttttttttt acgtgccagt acacctgcat cgacttctgt tgcttgccac 2241
 ggggcaaacac cgtgtttcaat cagccggatt gaaattcggtt acctacattg cgaatcatat 2301
 atttattttt ttagtattat tagtggtgca tgggtggttaa tgctccgcgt gcaccggccg 2361
 gccgcccgcg cgcccggcga gggcgggcga cgtctttaat aactagtcac aaatcagcat 2421
 gcatgctggc tctgcagct ggtgcgttga cattgtgcct ttgttcgttt cggctaatag 2481
 aattatatattg ctgggggtgtt gactttgttg tgatcgaacg ca ggc cat ggg gag 2535
 Gly His Gly Glu

atg gtg acg tgc tcc aag cag ctg aac gcg gac ctg ttc gac gcc gtc 2583
 Met Val Thr Cys Ser Lys Gln Leu Asn Ala Asp Leu Phe Asp Ala Val
 210 215 220 225

ctg ggc ggg ctg ggg cag ttc gga gtg atc acc cgg gcc cgg atc gcg 2631
 Leu Gly Gly Leu Gly Gln Phe Gly Val Ile Thr Arg Ala Arg Ile Ala
 230 235 240

SUBSTITUTE SHEET (rule 26)

gcc tac gcg gcg ttc ctt gac cgg gtg cac ggc gag gcg gtg gcg ctc 3063
 Ala Tyr Ala Ala Phe Leu Asp Arg Val His Gly Glu Glu Val Ala Leu 385
 370 375 380
 aac aag ctg ggg ctg tgg cgg gtg ccg cac ccg tgg ctc aac atg ttc 3111
 Asn Lys Leu Gly Leu Trp Arg Val Pro His Pro Trp Leu Asn Met Phe 400
 390 395 400
 gtg ccg cgc tcg cgc atc gcc gac ttc gac cgc ggc gtg ttc aag ggc 3159
 Val Pro Arg Ser Arg Ile Ala Asp Phe Asp Arg Gly Val Phe Lys Gly 415
 405 410 415
 atc ctg cag gcc acc gac atc gtc gcc ccg ctc atc gtc tac ccc ctc 3207
 Ile Leu Gln Gly Thr Asp Ile Val Gly Pro Leu Ile Val Tyr Pro Leu 430
 420 425 430
 aac aaa tcc atgtacgtgt tgaatcgatc ggctagctag ctagctaggc 3256
 Asn Lys Ser
 435
 acgccccggc cggcctctga cgactcgacc ggtcttcttg gggtttggtt ttcc atg 3313
 Met
 tgg gac gac gcc atg tcg gcg gcg acg ccg tct gag gac gcg gtg ttc tac 3361
 Trp Asp Asp Gly Met Ser Ala Ala Thr Pro Ser Glu Asp Val Phe Tyr 450
 440 445 450
 gcg gtg tcg ctg ctc ttc tcg tcg gtg gcg ccc aac gac ctg gcg agg 3409
 Ala Val Ser Leu Leu Phe Ser Ser Val Ala Pro Asn Asp Leu Ala Arg 465
 455 460 465

ctg cag gag cag aac agg agg atc ctg cgc ttc tgc gac ctc gcc ggc 3457
 Leu Gln Glu Gln Asn Arg Arg Ile Leu Arg Phe Cys Asp Leu Ala Gly
 470 475 480 485

 atc cag tac aag acc tac ctg gcg cgg cac acg gac cgc agt gac tgg 3505
 Ile Gln Tyr Lys Thr Tyr Leu Ala Arg His Thr Asp Arg Ser Asp Trp
 490 495 500

 gtc cgc cac ttc ggc gcc gcc aag tgg aat cgc ttc gtg gag atg aag 3553
 Val Arg His Phe Gly Ala Ala Lys Trp Asn Arg Phe Val Glu Met Lys
 505 510 515

 aac aag tac gac gcc aag agg ctg ctc tcc gcc cag gac atc ttc 3601
 Asn Lys Tyr Asp Pro Lys Arg Leu Leu Ser Pro Gly Ile Phe
 520 525 530

 aac tga tgatgatagc ccatgcatgt tttagtttct tgggacaata atgtgaataa 3657
 Asn

 ttcccagcta gcggctatta attaatctgt atatagattg atcactgcac tgatgtatgt 3717
 caaggtcatt atttacgtta tggtaaaaaa aaaagtaccc tcgtcgtata ttctcgtttc 3777
 atctgccccaa cccccagagt tttaaaaaatg cacgttgaga gcaaaaattc cacaccgttt 3837
 atccatgtag tagattgggt gtatatggaa tccgtataaa tatatagcaa gacaaaattt 3897
 attgcaaatct gatcccgtag accataattc acatgaaatt agaataaccg acaaaaagga 3957
 cttgttagta tgggttgccg ttgcactttt tttgtgtgcc tatttaggta tgatatagtt 4017
 ctgccaaca ttattgaca gtcaaatata tccctgtcgt cctaataaggc gtccaaaatc 4077

aaacgtgtgt ttagccagcc cccatccaaa caccgccata tccctatttt ctttgccttc 4137
ccttttaatt ttgttttttt ttctctcttc aaataataac tggctcctcaa ctagtcaatt 4197
aaaaaaaaag aagagtgtga aggagaagga aaaagacacc gtcacttgtg aaacaaaatta 4257
aaaagtttct tggatcgagg cgcgtgatac tctctcacc tgcacgtttt gcttcgatct 4317
ccgacggcac cgtccgtcat ttctacaaa atacgaaaacc ttgttccgtg cttgttgatc 4377
agacagctga cgtcgacaag ttcagggtaaa gggtcatttg cgcgaccagc aggtcggctg 4437
gtgttgaaact gattctttta aacttaatga taaccagtag agtagacacc attgattctt 4497
ttaaacttta accgctagtc ttattcaaaa tatttattta aaatgtataa ttttaaatca 4557
agcacagact acatcaagtg ataaaaacaaa tcataataaa attaatgata acttattatt 4617
gttttgaata agacgaacga tcaaagtttt aaaaaataaac ggtgtcatat acggaggagg 4677
tactagctta gtaccccggt tgaccagaag tgcggtgtgc cttaattcga tcgttttctc 4737
ttgtttcctc agcgttcacc acatgcactg cacttgcaag ccgtacacgt tgactagtgg 4797
ggcaatgcta gcttgggtgag gttttttgat tgattcccag ctttttagacg aggtcactcc 4857
acaaaaaaaag ctaagcaacg gtgctgacct gaataaataa aggtgggtcgt agattattgg 4917
ttatagccgt cgtcacaggt cacacacacg caacaagcct atagcaggat tacaccgatt 4977
atcatcggga aatagaaaaa agggaaatga acgaagtaac caggagacag acgacgagaa 5037
agtattgtct atccttaaga ccccttgag caagctacac ggataattag gctcccatcg 5097

gacgtcattt ctggacacgt acgctattgt gatttghtaag ggtgttttgggt ttctaaatac 5157
taatttttttag ccactcttta ttattatatt ctagtcacta aattatcaaa tacgaaaatt 5217
aaaaatagatt tttaatttta agtatttttgt aattttatgta ctagaatgga ataaaaatgggt 5277
gtgattaaaa attagtcctt aaaaatcaaa tgtcattccc cctttattag aagacctctt 5337
gagcaagcta agctgcacgt attattaggc ctcaacatgc ctatgtgtgt ataacaggac 5397
aaccaggccc ccaaaacttc agtgtacgt atgtgtaaca tgtactgtga ggacaaatcga 5457
tctcaaacgt cagctgtagg tacgtatgaa tgtatatatg tgtatttact cctcctgttt 5517
taaatcagtt gtcgcgatgg tattttatgtc catcaaaagt tgttagagta gactagcttt 5577
ttagaaaaatg ttagtcacat ttatatcctc aaataaaactt acttataaaa ataaattcaa 5637
tgatctattt aataatataa cgataactaat catgtaatat gaatataaat attttcttgn 5697
acatatattga tgaagtthta aatagttagt ttttaaaaaa ataaaaaacac cgactatttt 5757
aaaaatagata ggtacacatat acaagaaaaa gagaaattat tactaatgtt tacaacgtat 5817
aataaataat atataaatta tgaatatatat ttttataata aatctgttta gagaagataa 5877
tattttctac gactccttgt tcaaatctag aatgacatta tttttgggac ggaggcagtt 5937
cgtactacgt acgtaaacatg tattcctaac acggacaatc aaaacatggg aacttcactc 5997
catttgtaaa gccgggggag gaatcgggtgg amgtgtttgt ttcttggcgc acggtgaytc 6057
gatgaggatt cgtgcaaac ttaamaggct tggtcactctg tctgcattca ytcacacgg 6117

5

10

15

20

ccatacgcac gtgttttttct ggatgggcat gaacacggac acggcacgca tctcaagtca 6177
gggcagttaa agggagacgc gtgggaacat gataccaggg ttgcatcttc acaaaattgg 6237
5 ccgtatgtgc tacatcatca gggggagcag ccataattta catggaaaacg aatacaatga 6297
tggagcacgt cagtggctat tattcttcaa tgaggctaca gctacactat ttgatgcaca 6357
tcagctactg cctcctagtc cttggggccc cacctccaca ctttcagctc gccggagcag 6417
10 tctccgggtga agagcagccc accagccgca agctcgatgg tcctaacttc cttcgtggac 6477
aacagtgttc caatcccgtc gaacctgaaa gatggtaacc aggcaaatgc agagctcctt 6537
tcagtaagga accactgagc gagcggtttg tctatctgat gatgaaactg ataaaaaaa 6597
15 attatgcact cagcatggca agtcgagcaa gcggacgcga ttgctgttgt ggaggaggca 6657
caagagaact ggcgtcttcc caactcgggtg catgccgaag agtgtgcgca aaccctgcaa 6717
cataatcgga aagctt 6733
20 <210> 3
<211> 1605
<212> DNA
<213> Zea mays
25 <220>
<221> CDS
<222> (1)..(1605)

```

<400> 3
atg gcg gtt tat tac ctg ctg ggg ctg atc gcc tgc tct 48
Met Ala Val Tyr Tyr 5
1
cat gca cta gcg gca ggc acg cct gcg ctg gga gat cgc ggc cgt 96
His Ala Leu Ala Ala Gly Thr Pro Ala Leu Gly Asp Arg Gly Arg
20
ccc tgg cca gcc tcc ctg ggc ggc ggc ggc ggc ggc ggc ggc 144
Pro Trp Pro Ala Ser Leu Ala Ala Ala Leu Asp Gly Lys Leu Arg
35
acc gac agc aac gcg acg gcg gcc gcg ggc ttc ggc aac atc 192
Thr Asp Ser Asn Ala Thr Ala Ala Val Ser Thr Asp Phe Gly Asn Ile
50
acg tcg gcg ctc ccg gcg gtc ctg tac ccg tcg tcc acg ggc gac 240
Thr Ser Ala Leu Pro Ala Ala Val Leu Tyr 75
65
ctg gtg gcg ctg agc gcg gcc aac tcc acc ccg ggc tgg ccc tac 288
Leu Val Ala Leu Leu Ser Ala Ala Val Ser Thr Pro Gly Trp 95
85
acc atc gcg ttc cgc ggc cgc ggc cac tcc ctg ggc cag gcc ttc 336
Thr Ile Ala Phe Arg Gly Arg Gly His Ser Leu Met Gly Gln Ala Phe
100
gcc ccc gcc ggc gtc gtc gtc aac atg gcg tcc ctg ggc gac gcc gcc 384
Ala Pro Gly Gly Val Val Val Asn Met Ala Ser Leu Gly Asp Ala Ala
115

```

SUBSTITUTE SHEET (rule 26)

gcg ccg ccg cgc atc aac gtg tcc gcg gac ggc cgc tac gtg gac gcc 432
Ala Pro Pro Arg Ile Asn Val Ser Ala Asp Gly Arg Tyr Val Asp Ala
130 135 140

480
 ggc ggc gag cag gtg atc gac gtg ttg cgc ggc tgc ctg ggc cgc
 Gly Gly Glu Gln Val Trp Ile Asp Val Leu 155 Arg Ala Arg
 145
 528
 ggc gtg ggc ccg cgc tcc tgg aac gac tac ctc tac ctc acc gtc ggc
 Gly Val Ala Pro Arg Ser Trp Asn Asp Tyr Leu Tyr Thr Val Gly
 165
 576
 ggc acg ctg tcc aac gca ggc atc agc ggc cag ggc ttc cgc cac ggc
 Gly Thr Leu Ser Asn Ala Gly Ile Ser Gly Gln Ala Phe Arg His Gly
 180
 624
 cca cag ata tct aac gtg ctg gag atg gac gtt atc acc ggc cat ggc
 Pro Gln Ile Ser Asn Val Leu Glu Met Asp Val Ile Thr Gly His Gly
 195
 672
 gag atg gtg acg tgc tcc aag cag ctg aac ggc gac ctg ttc gac gcc
 Glu Met Val Thr Cys Ser Lys Gln Leu Asn Ala Asp Phe Asp Ala
 210
 720
 gtc ctg ggc ggc ctg ggc cag ttc gga gtg atc acc cgc gcc cgc atc
 Val Leu Gly Gly Leu 230 Ile Thr Arg Ala Arg Ile
 225
 768
 ggc gtg gag ccg ggc ccg ggc cgc ggc ggc tgg gtg cgc ttc gtg tac
 Ala Val Glu Pro Ala Pro Ala Arg Ala Arg Trp Val Arg Phe Val Tyr
 245
 816
 acc gac ttc ggc ggc ttc agc gcc gac cag gag cgc ctg acc gcc ccg
 Thr Asp Phe Ala Ala Phe Ser Ala Asp Gln Glu Arg Leu Thr Ala Pro
 260

SUBSTITUTE SHEET (rule 26)

5	<p> ttc gtg ccg cgc tcg cgc atc gcc gac ttc gac cgc ggc gtg ttc aag 1248 Phe Val Pro Arg Ser Arg Ile Ala Asp Phe Asp Arg Gly Val Phe Lys 405 410 415 </p> <p> ggc atc ctg cag ggc acc gac atc gtc ggc ccg ctc atc gtc tac ccc 1296 Gly Ile Leu Gln Gly Thr Asp Ile Val Gly Pro Leu Ile Val Tyr Pro 420 425 430 </p> <p> ctc aac aaa tcc atg tgg gac gac ggc atg tcg gcg acg ccg tct 1344 Leu Asn Lys Ser Met Trp Asp Asp Gly Met Ser Ala Ala Thr Pro Ser 435 440 445 </p>
10	<p> gag gac gtg ttc tac gcg gtg tcg ctg ctc ttc tcg tcg gtg gcg ccc 1392 Glu Asp Val Phe Tyr Ala Val Ser Leu Leu Phe Ser Ser Val Ala Pro 450 455 460 </p> <p> aac gac ctg gcg agg ctg cag gag cag ggc atc ctg cgc ttc 1440 Asn Asp Leu Ala Arg Leu Gln Glu Gln Asn Arg Arg Ile Leu Arg Phe 465 470 475 480 </p> <p> tgc gac ctc gcc ggg atc cag tac aag acc tcg gcg cgc cac acg 1488 Cys Asp Leu Ala Gly Ile Gln Tyr Lys Thr Tyr Leu Ala Arg His Thr 485 490 495 </p> <p> gag cgc agt gac tgg gtc cgc cac ttc ggc gcc gcc aag tgg aat cgc 1536 Asp Arg Ser Asp Trp Val Arg His Phe Gly Ala Ala Lys Trp Asn Arg 500 505 510 </p> <p> ttc gtg gag atg aag aac aag tac gac ccc aag agg ctg ctc tcc ccc 1584 Phe Val Glu Met Lys Asn Lys Tyr Asp Pro Lys Arg Leu Leu Ser Pro 515 520 525 </p>
15	
20	

1605

ggc cag gac atc ttc aac tga
 Gly Gln Asp Ile Phe Asn
 530

5 <210> 4
 <211> 21
 <212> PRT
 <213> Zea mays

10 <220>
 <221> VARIANT
 <222> (9)

15 <400> 4
 Tyr Val Glu Gly Ser Val Phe Val Xaa Gln Ser Leu Ala Thr Asp Leu
 1 5 10 15
 Ala Asn Thr Gly Phe
 20

20 <210> 5
 <211> 15
 <212> PRT
 <213> Zea mays

<400> 5
 Gly Ile Leu Gln Gly Thr Asp Ile Val Gly Pro Leu Ile Val Tyr
 1 5 10 15

<210> 6
<211> 23
<212> DNA
<213> Zea mays

5

<220>
<221> modified_base
<222> (6)
<223> i

10

<220>
<221> modified_base
<222> (12)
<223> i

15

<220>
<221> modified_base
<222> (15)
<223> i

20

<220>
<221> modified_base
<222> (18)
<223> i

25

<400> 6
tacgtngayg gnwsngtntt cgt

30

<210> 7
<211> 23
<212> DNA
<213> Zea mays

23

5 <220> modified_base
 <221> (3)
 <222> i
 <223> i

10 <220> modified_base
 <221> (9)
 <222> i
 <223> i

15 <220> modified_base
 <221> (12)
 <222> i
 <223> i

20 <220> modified_base
 <221> (18)
 <222> i
 <223> i

25 <220> modified_base
 <221> (21)
 <222> i
 <223> i

 <400> 7
 acngayctng cnaacacngg ntt

30 <210> 8
 <211> 23
 <212> DNA
 <213> Zea mays

23

<220>
<221> modified_base
<222> (3)
<223> i

5

<220>
<221> modified_base
<222> (9)
<223> i

10

<220>
<221> modified_base
<222> (15)
<223> i

15

<220>
<221> modified_base
<222> (18)
<223> i

<400> 8
ccntargang tcccntgnct rta

23

20

<210> 9
<211> 23
<212> DNA
<213> Zea mays

25

<220>
<221> modified_base
<222> (6)
<223> i

5
 <220>
 <221> modified_base
 <222> (9)
 <223> i

 <220>
 <221> modified_base
 <222> (12)
 <223> i

 10
 <220>
 <221> modified_base
 <222> (15)
 <223> i

 15
 <220>
 <221> modified_base
 <222> (21)
 <223> i

 20
 <400> 9
 tarcancng gngantarca nat

 25
 <210> 10
 <211> 1602
 <212> DNA
 <213> Zea mays

 30
 <220>
 <221> variation
 <222> (6)
 <223> a,g,c or t
 i

23

SUBSTITUTE SHEET (rule 26)

5 <220> variation
 <221> (9)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (12)
 <222> a, g, c or t
 <223>

10 <220> variation
 <221> (21)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (24)
 <222> a, g, c or t
 <223>

15 <220> variation
 <221> (27)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (30)
 <222> a, g, c or t
 <223>

20 <220> variation
 <221> (33)
 <222>
 <223>

25 <220> variation
 <221> (33)
 <222>
 <223>

30 <220> variation
 <221> (33)
 <222>
 <223>

SUBSTITUTE SHEET (rule 26)

<223> a,g,c or t
<220>
<221> variation
<222> (36)
<223> a,g,c or t
5
<220>
<221> variation
<222> (42)
<223> a,g,c or t
10
<220>
<221> variation
<222> (48)
<223> a,g,c or t
15
<220>
<221> variation
<222> (54)
<223> a,g,c or t
20
<220>
<221> variation
<222> (57)
<223> a,g,c or t
25
<220>
<221> variation
<222> (60)
<223> a,c,g or t
30

5	<220> <221> variation <222> (63) <223> a,g,c or t
10	<220> <221> variation <222> (66) <223> a,g,c or t
15	<220> <221> variation <222> (69) <223> a,g,c or t
20	<220> <221> variation <222> (72) <223> a,g,c or t
25	<220> <221> variation <222> (75) <223> a,g,c or t
30	<220> <221> variation <222> (78) <223> a,g,c or t

5 <220> variation
 <221> (81)
 <222> a,g,c or t
 <223>

10 <220> variation
 <221> (90)
 <222> a,g,c or t
 <223>

15 <220> variation
 <221> (93)
 <222> a,g,c or t
 <223>

20 <220> variation
 <221> (96)
 <222> a,g,c or t
 <223>

25 <220> variation
 <221> (99)
 <222> a,g,c or t
 <223>

 <220> variation
 <221> (105)
 <222> a,g,c or t
 <223>

5 <220> variation
 <221> (108)
 <222> a, g, c or t
 <223> a, g, c or t

10 <220> variation
 <221> (111)
 <222> a, g, c or t
 <223> a, g, c or t

15 <220> variation
 <221> (114)
 <222> a, g, c or t
 <223> a, g, c or t

20 <220> variation
 <221> (117)
 <222> a, g, c or t
 <223> a, g, c or t

25 <220> variation
 <221> (120)
 <222> a, g, c or t
 <223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

	<220>	
	<221>	variation
	<222>	(126)
	<223>	a,g,c or t
5	<220>	
	<221>	variation
	<222>	(129)
	<223>	a,g,c or t
10	<220>	
	<221>	variation
	<222>	(135)
	<223>	a,g,c or t
15	<220>	
	<221>	variation
	<222>	(141)
	<223>	a,g,c or t
20	<220>	
	<221>	variation
	<222>	(144)
	<223>	a,g,c or t
25	<220>	
	<221>	variation
	<222>	(147)
	<223>	a,g,c or t

<220>
<221> variation
<222> (153)
<223> a, g, c or t

5

<220>
<221> variation
<222> (159)
<223> a, c, g or t

10

<220>
<221> variation
<222> (162)
<223> a, g, c or t

15

<220>
<221> variation
<222> (165)
<223> a, g, c or t

20

<220>
<221> variation
<222> (168)
<223> a, g, c or t

25

<220>
<221> variation
<222> (171)
<223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

5
10
15
20
25

<220> variation
<221> (174)
<222> a, g, c or t
<223> a, g, c or t

<220> variation
<221> (177)
<222> a, g, c or t
<223> a, g, c or t

<220> variation
<221> (186)
<222> a, g, c or t
<223> a, g, c or t

<220> variation
<221> (195)
<222> a, g, c or t
<223> a, g, c or t

<220> variation
<221> (198)
<222> a, g, c or t
<223> a, g, c or t

<220> variation
<221> (201)
<222> a, g, c or t
<223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

5 <220> variation
 <221> (204)
 <222> a, g, c or t
 <223> a, g, c or t

10 <220> variation
 <221> (207)
 <222> a, g, c or t
 <223> a, g, c or t

15 <220> variation
 <221> (210)
 <222> a, g, c or t
 <223> a, g, c or t

20 <220> variation
 <221> (213)
 <222> a, g, c or t
 <223> a, g, c or t

25 <220> variation
 <221> (216)
 <222> a, g, c or t
 <223> a, g, c or t

5
10
15
20
25

<220> variation
<221> (225)
<222> a, g, c or t
<223> variation
<221> (228)
<222> a, g, c or t
<223> variation
<221> (231)
<222> a, g, c or t
<223> variation
<221> (234)
<222> a, g, c or t
<223> variation
<221> (237)
<222> a, g, c or t
<223> variation
<221> (243)
<222> a, g, c or t

SUBSTITUTE SHEET (rule 26)

<220>
<221> variation
<222> (246)
<223> a,g,c or t

5

<220>
<221> variation
<222> (249)
<223> a,g,c or t

10

<220>
<221> variation
<222> (252)
<223> a,g,c or t

15

<220>
<221> variation
<222> (255)
<223> a,c,g or t

20

<220>
<221> variation
<222> (258)
<223> a,g,c or t

25

<220>
<221> variation
<222> (261)
<223> a,g,c or t

SUBSTITUTE SHEET (rule 26)

	<220> variation
	<221> (264)
	<222> a, g, c or t
5	<220> variation
	<221> (270)
	<222> a, g, c or t
10	<220> variation
	<221> (273)
	<222> a, g, c or t
15	<220> variation
	<221> (276)
	<222> a, g, c or t
20	<220> variation
	<221> (279)
	<222> a, g, c or t
25	<220> variation
	<221> (285)
	<222> a, g, c or t

5 <220> variation
 <221> (291)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (297)
 <222> a, g, c or t
 <223>

10 <220> variation
 <221> (303)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (306)
 <222> a, g, c or t
 <223>

15 <220> variation
 <221> (309)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (312)
 <222> a, g, c or t
 <223>

20

SUBSTITUTE SHEET (rule 26)

5 <220> variation
 <221> (318)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (321)
 <222> a, g, c or t
 <223>

10 <220> variation
 <221> (327)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (333)
 <222> a, g, c or t
 <223>

15 <220> variation
 <221> (339)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (342)
 <222> a, g, c or t
 <223>

20 <220>
 <221>
 <222>
 <223>

25 <220>
 <221>
 <222>
 <223>

SUBSTITUTE SHEET (rule 26)

5 <220> variation
 <221> (345)
 <222> a, g, c or t
 <223> a, g, c or t

10 <220> variation
 <221> (348)
 <222> a, g, c or t
 <223> a, g, c or t

15 <220> variation
 <221> (351)
 <222> a, g, c or t
 <223> a, g, c or t

20 <220> variation
 <221> (354)
 <222> a, g, c or t
 <223> a, g, c or t

25 <220> variation
 <221> (357)
 <222> a, g, c or t
 <223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

5	<220> <221> variation <222> (369) <223> a,g,c or t
10	<220> <221> variation <222> (372) <223> a,g,c or t
15	<220> <221> variation <222> (375) <223> a,g,c or t
20	<220> <221> variation <222> (381) <223> a,g,c or t
25	<220> <221> variation <222> (384) <223> a,g,c or t

SUBSTITUTE SHEET (rule 26)

5	<220> <221> variation <222> (390) <223> a, g, c or t
10	<220> <221> variation <222> (393) <223> a, g, c or t
15	<220> <221> variation <222> (396) <223> a, g, c or t
20	<220> <221> variation <222> (405) <223> a, g, c or t
25	<220> <221> variation <222> (408) <223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

<220> variation
<221> (417)
<222> a, g, c or t
<223> a, g, c or t

5

<220> variation
<221> (420)
<222> a, g, c or t
<223> a, g, c or t

10

<220> variation
<221> (426)
<222> a, g, c or t
<223> a, g, c or t

15

<220> variation
<221> (432)
<222> a, g, c or t
<223> a, g, c or t

20

<220> variation
<221> (435)
<222> a, g, c or t
<223> a, g, c or t

25

<220> variation
<221> (438)
<222> a, g, c or t
<223> a, g, c or t

5 <220> variation
 <221> (447)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (459)
 <222> a, g, c or t
 <223>

10 <220> variation
 <221> (462)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (465)
 <222> a, g, c or t
 <223>

15 <220> variation
 <221> (468)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (471)
 <222> a, g, c or t
 <223>

20 <220>
 <221>
 <222>
 <223>

 <220>
 <221>
 <222>
 <223>

25 <220>
 <221>
 <222>
 <223>

SUBSTITUTE SHEET (rule 26)

	<220>	
	<221>	variation
	<222>	(474)
	<223>	a, g, c or t
5	<220>	
	<221>	variation
	<222>	(477)
	<223>	a, c, g or t
10	<220>	
	<221>	variation
	<222>	(480)
	<223>	a, g, c or t
15	<220>	
	<221>	variation
	<222>	(483)
	<223>	a, g, c or t
20	<220>	
	<221>	variation
	<222>	(486)
	<223>	a, g, c or t
	<220>	
	<221>	variation
	<222>	(489)
	<223>	a, g, c or t

SUBSTITUTE SHEET (rule 26)

<220>
<221> variation
<222> (492)
<223> a, g, c or t

5

<220>
<221> variation
<222> (495)
<223> a, g, c or t

10

<220>
<221> variation
<222> (498)
<223> a, g, c or t

15

<220>
<221> variation
<222> (513)
<223> a, g, c or t

20

<220>
<221> variation
<222> (519)
<223> a, g, c or t

25

<220>
<221> variation
<222> (522)
<223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

	<220>	
	<221>	variation
	<222>	(525)
	<223>	a, g, c or t
5	<220>	
	<221>	variation
	<222>	(528)
	<223>	a, g, c or t
10	<220>	
	<221>	variation
	<222>	(531)
	<223>	a, g, c or t
15	<220>	
	<221>	variation
	<222>	(534)
	<223>	a, g, c or t
20	<220>	
	<221>	variation
	<222>	(537)
	<223>	a, g, c or t
	<220>	
	<221>	variation
	<222>	(540)
	<223>	a, g, c or t

5	<220> <221> variation <222> (546) <223> a, g, c or t
10	<220> <221> variation <222> (549) <223> a, g, c or t
15	<220> <221> variation <222> (555) <223> a, g, c or t
20	<220> <221> variation <222> (558) <223> a, g, c or t
25	<220> <221> variation <222> (564) <223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

5
 <220>
 <221> variation
 <222> (576)
 <223> a, g, c or t

10
 <220>
 <221> variation
 <222> (579)
 <223> a, g, c or t

15
 <220>
 <221> variation
 <222> (588)
 <223> a, g, c or t

20
 <220>
 <221> variation
 <222> (594)
 <223> a, c, g or t

 <220>
 <221> variation
 <222> (597)
 <223> a, g, c or t

 <220>
 <221> variation
 <222> (609)
 <223> a, g, c or t

```
<220> variation
<221> (615)
<222> a,g,c or t
<223>
```

5

```
<220> variation
<221> (618)
<222> a,g,c or t
<223>
```

```
<220> variation
<221> (624)
<222> a,g,c or t
<223>
```

10

```
<220> variation
<221> (633)
<222> a, g, c or t
<223>
```

15

```
<220> variation
<221> (637)
<222> a, g, c or t
<223>
```

20

```
<220>
<221> variation
<222> (642)
<223> a, g, c or t
```

SUBSTITUTE SHEET (rule 26)

<220>
<221> variation
<222> (651)
<223> a,g,c or t

5

<220>
<221> variation
<222> (657)
<223> a,g,c or t

10

<220>
<221> variation
<222> (663)
<223> a,g,c or t

<220>
<221> variation
<222> (672)
<223> a,g,c or t

15

<220>
<221> variation
<222> (675)
<223> a,g,c or t

20

<220>
<221> variation
<222> (678)
<223> a,g,c or t

25

SUBSTITUTE SHEET (rule 26)

<220>
<221> variation
<222> (681)
<223> a, g, c or t

5

<220>
<221> variation
<222> (684)
<223> a, g, c or t

10

<220>
<221> variation
<222> (687)
<223> a, g, c or t

15

<220>
<221> variation
<222> (690)
<223> a, g, c or t

20

<220>
<221> variation
<222> (699)
<223> a, g, c or t

<220>
<221> variation
<222> (702)
<223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

5	<220> <221> variation <222> (708) <223> a,g,c or t
10	<220> <221> variation <222> (711) <223> a,g,c or t
15	<220> <221> variation <222> (717) <223> a,g,c or t
20	<220> <221> variation <222> (723) <223> a,g,c or t
25	<220> <221> variation <222> (726) <223> a,g,c or t

<220>
<221> variation
<222> (735)
<223> a,g,c or t

5

<220>
<221> variation
<222> (738)
<223> a,g,c or t

10

<220>
<221> variation
<222> (741)
<223> a,g,c or t

15

<220>
<221> variation
<222> (744)
<223> a,g,c or t

20

<220>
<221> variation
<222> (747)
<223> a,g,c or t

25

<220>
<221> variation
<222> (750)
<223> a,g,c or t

5	<220> <221> variation <222> (756) <223> a,g,c or t
10	<220> <221> variation <222> (759) <223> a,g,c or t
15	<220> <221> variation <222> (771) <223> a,g,c or t
20	<220> <221> variation <222> (780) <223> a,g,c or t
25	<220> <221> variation <222> (783) <223> a,g,c or t

<220>
<221> variation
<222> (789)
<223> a, g, c or t

<220>
<221> variation
<222> (792)
<223> a, g, c or t

<220>
<221> variation
<222> (804)
<223> a, g, c or t

<220>
<221> variation
<222> (807)
<223> a, g, c or t

<220>
<221> variation
<222> (810)
<223> a, g, c or t

<220>
<221> variation
<222> (813)
<223> a, g, c or t

5

10

15

20

25

SUBSTITUTE SHEET (rule 26)

5 <220> variation
 <221> (816)
 <222> a, g, c or t
 <223> a, g, c or t

10 <220> variation
 <221> (819)
 <222> a, g, c or t
 <223> a, g, c or t

15 <220> variation
 <221> (822)
 <222> a, g, c or t
 <223> a, g, c or t

20 <220> variation
 <221> (825)
 <222> a, g, c or t
 <223> a, g, c or t

25 <220> variation
 <221> (828)
 <222> a, g, c or t
 <223> a, g, c or t

5
 <220>
 <221> variation
 <222> (834)
 <223> a, g, c or t

10
 <220>
 <221> variation
 <222> (837)
 <223> a, c, g or t

15
 <220>
 <221> variation
 <222> (840)
 <223> a, g, c or t

20
 <220>
 <221> variation
 <222> (846)
 <223> a, g, c or t

25
 <220>
 <221> variation
 <222> (849)
 <223> a, g, c or t

 <220>
 <221> variation
 <222> (855)
 <223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

5
10
15
20

<220> variation
<221> (861)
<222> a, g, c or t
<223> variation
<221> (867)
<222> a, g, c or t
<223> variation
<221> (870)
<222> a, g, c or t
<223> variation
<221> (873)
<222> a, g, c or t
<223> variation
<221> (879)
<222> a, g, c or t
<223> variation
<221> (888)
<222> a, g, c or t
<223>

<220>
<221> variation
<222> (891)
<223> a,g,c or t

5

<220>
<221> variation
<222> (894)
<223> a,g,c or t

10

<220>
<221> variation
<222> (897)
<223> a,g,c or t

15

<220>
<221> variation
<222> (903)
<223> a,g,c or t

20

<220>
<221> variation
<222> (906)
<223> a,g,c or t

25

<220>
<221> variation
<222> (912)
<223> a,g,c or t

SUBSTITUTE SHEET (rule 26)

	<220>	
	<221>	variation
	<222>	(915)
	<223>	a,g,c or t
5	<220>	
	<221>	variation
	<222>	(924)
	<223>	a,g,c or t
10	<220>	
	<221>	variation
	<222>	(930)
	<223>	a,g,c or t
15	<220>	
	<221>	variation
	<222>	(936)
	<223>	a,g,c or t
20	<220>	
	<221>	variation
	<222>	(939)
	<223>	a,g,c or t
25	<220>	
	<221>	variation
	<222>	(942)
	<223>	a,c,g or t

SUBSTITUTE SHEET (rule 26)

	<220>	
	<221>	variation
	<222>	(948)
	<223>	a, g, c or t
5	<220>	
	<221>	variation
	<222>	(951)
	<223>	a, g, c or t
10	<220>	
	<221>	variation
	<222>	(954)
	<223>	a, g, c or t
15	<220>	
	<221>	variation
	<222>	(957)
	<223>	a, g, c or t
20	<220>	
	<221>	variation
	<222>	(960)
	<223>	a, g, c or t
25	<220>	
	<221>	variation
	<222>	(966)
	<223>	a, g, c or t

SUBSTITUTE SHEET (rule 26)

5 <220> variation
 <221> (972)
 <222> a, g, c or t
 <223> a, g, c or t

10 <220> variation
 <221> (975)
 <222> a, g, c or t
 <223> a, g, c or t

15 <220> variation
 <221> (978)
 <222> a, g, c or t
 <223> a, g, c or t

20 <220> variation
 <221> (987)
 <222> a, g, c or t
 <223> a, g, c or t

 <220> variation
 <221> (996)
 <222> a, g, c or t
 <223> a, g, c or t

 <220> variation
 <221> (999)
 <222> a, g, c or t
 <223> a, g, c or t

<220>
<221> variation
<222> (1002)
<223> a, g, c or t

5

<220>
<221> variation
<222> (1017)
<223> a, g, c or t

10

<220>
<221> variation
<222> (1020)
<223> a, g, c or t

15

<220>
<221> variation
<222> (1023)
<223> a, g, c or t

20

<220>
<221> variation
<222> (1026)
<223> a, g, c or t

25

<220>
<221> variation
<222> (1029)
<223> a, g, c or t

<220>
<221> variation
<222> (1032)
<223> a,g,c or t

5

<220>
<221> variation
<222> (1035)
<223> a,g,c or t

10

<220>
<221> variation
<222> (1038)
<223> a,g,c or t

15

<220>
<221> variation
<222> (1050)
<223> a,g,c or t

20

<220>
<221> variation
<222> (1053)
<223> a,g,c or t

25

<220>
<221> variation
<222> (1056)
<223> a,g,c or t

SUBSTITUTE SHEET (rule 26)

<220>
<221> variation
<222> (1059)
<223> a, g, c or t

5

<220>
<221> variation
<222> (1062)
<223> a, c, g or t

10

<220>
<221> variation
<222> (1065)
<223> a, g, c or t

15

<220>
<221> variation
<222> (1068)
<223> a, g, c or t

20

<220>
<221> variation
<222> (1071)
<223> a, g, c or t

25

<220>
<221> variation
<222> (1074)
<223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

5
10
15
20
25

<220>
<221> variation
<222> (1080)
<223> a, g, c or t

<220>
<221> variation
<222> (1086)
<223> a, g, c or t

<220>
<221> variation
<222> (1092)
<223> a, g, c or t

<220>
<221> variation
<222> (1101)
<223> a, g, c or t

<220>
<221> variation
<222> (1107)
<223> a, g, c or t

<220>
<221> variation
<222> (1110)
<223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

<220>
<221> variation
<222> (1116)
<223> a,g,c or t

<220>
<221> variation
<222> (1119)
<223> a,g,c or t

<220>
<221> variation
<222> (1125)
<223> a,g,c or t

<220>
<221> variation
<222> (1131)
<223> a,g,c or t

<220>
<221> variation
<222> (1134)
<223> a,g,c or t

<220>
<221> variation
<222> (1140)
<223> a,g,c or t

5

10

15

20

25

SUBSTITUTE SHEET (rule 26)

5

10

15

20

25

```
<220> variation
<221> (1170)
<222> a,g,c or t
<223>
```

<220>
<221> variation
<222> (1176)
<223> a, g, c or t

<220>
<221> variation
<222> (1182)
<223> a, g, c or t

<220>
<221> variation
<222> (1188)
<223> a, g, c or t

<220>
<221> variation
<222> (1194)
<223> a, c, g or t

<220>
<221> variation
<222> (1206)
<223> a, g, c or t

<220>
<221> variation
<222> (1209)
<223> a, g, c or t

5

10

15

20

25

SUBSTITUTE SHEET (rule 26)

5
10
15
20

<220> variation
<221> (1212)
<222> a,g,c or t
<223> variation
<221> (1215)
<222> a,g,c or t
<223> variation
<221> (1218)
<222> a,g,c or t
<223> variation
<221> (1224)
<222> a,g,c or t
<223> variation
<221> (1236)
<222> a,g,c or t
<223> variation
<221> (1239)
<222> a,g,c or t
<223>

5
10
15
20
25

<220>
<221> variation
<222> (1242)
<223> a, g, c or t

<220>
<221> variation
<222> (1251)
<223> a, g, c or t

<220>
<221> variation
<222> (1257)
<223> a, g, c or t

<220>
<221> variation
<222> (1263)
<223> a, g, c or t

<220>
<221> variation
<222> (1266)
<223> a, g, c or t

<220>
<221> variation
<222> (1275)
<223> a, g, c or t

<220>
<221> variation
<222> (1278)
<223> a, g, c or t

5

<220>
<221> variation
<222> (1281)
<223> a, g, c or t

10

<220>
<221> variation
<222> (1284)
<223> a, g, c or t

15

<220>
<221> variation
<222> (1290)
<223> a, g, c or t

20

<220>
<221> variation
<222> (1296)
<223> a, g, c or t

<220>
<221> variation
<222> (1299)
<223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

<220>
<221> variation
<222> (1308)
<223> a,g,c or t

5

<220>
<221> variation
<222> (1323)
<223> a,g,c or t

<220>
<221> variation
<222> (1329)
<223> a,g,c or t

10

<220>
<221> variation
<222> (1332)
<223> a,g,c or t

15

<220>
<221> variation
<222> (1335)
<223> a,g,c or t

20

<220>
<221> variation
<222> (1338)
<223> a,c,g or t

25

SUBSTITUTE SHEET (rule 26)

5
10
15
20

<220> variation
<221> (1341)
<222> a, g, c or t
<223> variation
<221> (1344)
<222> a, g, c or t
<223> variation
<221> (1353)
<222> a, g, c or t
<223> variation
<221> (1362)
<222> a, g, c or t
<223> variation
<221> (1365)
<222> a, g, c or t
<223> variation
<221> (1368)
<222> a, g, c or t
<223> a, g, c or t

5 <220> variation
 <221> (1371)
 <222> a, g, c or t
 <223>

10 <220> variation
 <221> (1374)
 <222> a, g, c or t
 <223>

15 <220> variation
 <221> (1380)
 <222> a, g, c or t
 <223>

20 <220> variation
 <221> (1383)
 <222> a, g, c or t
 <223>

25 <220> variation
 <221> (1386)
 <222> a, g, c or t
 <223>

 <220> variation
 <221> (1389)
 <222> a, g, c or t
 <223>

SUBSTITUTE SHEET (rule 26)

5
10
15
20

<220> variation
<221> (1392)
<222> a, g, c or t
<223> variation
<221> (1401)
<222> a, g, c or t
<223> variation
<221> (1404)
<222> a, g, c or t
<223> variation
<221> (1410)
<222> a, g, c or t
<223> variation
<221> (1425)
<222> a, g, c or t
<223> variation
<221> (1428)
<222> a, g, c or t
<223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

5 <220> variation
 <221> (1434)
 <222> a, g, c or t
 <223> a, g, c or t

10 <220> variation
 <221> (1437)
 <222> a, g, c or t
 <223> a, g, c or t

15 <220> variation
 <221> (1449)
 <222> a, g, c or t
 <223> a, g, c or t

20 <220> variation
 <221> (1452)
 <222> a, g, c or t
 <223> a, g, c or t

25 <220> variation
 <221> (1455)
 <222> a, g, c or t
 <223> a, g, c or t

SUBSTITUTE SHEET (rule 26)

5
10
15
20
25

<220> variation
<221> (1476)
<222> a,g,c or t
<223> a,g,c or t

<220> variation
<221> (1479)
<222> a,g,c or t
<223> a,g,c or t

<220> variation
<221> (1482)
<222> a,g,c or t
<223> a,g,c or t

<220> variation
<221> (1488)
<222> a,g,c or t
<223> a,g,c or t

<220> variation
<221> (1494)
<222> a,g,c or t
<223> a,g,c or t

<220> variation
<221> (1497)
<222> a,g,c or t
<223> a,g,c or t

	<220>	
	<221>	variation
	<222>	(1506)
	<223>	a, g, c or t
5	<220>	
	<221>	variation
	<222>	(1509)
	<223>	a, g, c or t
10	<220>	
	<221>	variation
	<222>	(1518)
	<223>	a, g, c or t
15	<220>	
	<221>	variation
	<222>	(1521)
	<223>	a, g, c or t
20	<220>	
	<221>	variation
	<222>	(1524)
	<223>	a, g, c or t
25	<220>	
	<221>	variation
	<222>	(1536)
	<223>	a, g, c or t

SUBSTITUTE SHEET (rule 26)

<220>
<221> variation
<222> (1542)
<223> a,g,c or t

5

<220>
<221> variation
<222> (1566)
<223> a,g,c or t

10

<220>
<221> variation
<222> (1572)
<223> a,g,c or t

15

<220>
<221> variation
<222> (1575)
<223> a,g,c or t

20

<220>
<221> variation
<222> (1578)
<223> a,g,c or t

25

<220>
<221> variation
<222> (1581)
<223> a,g,c or t

SUBSTITUTE SHEET (rule 26)

<220>
 <221> variation
 <222> (1584)
 <223> a,g,c or t

5

<220>
 <221> variation
 <222> (1587)
 <223> a,g,c or t

10

<400> 10
 atggcngtng tntaytayyt nytnytnngcn ggnytnathg cntgywsnca ygcnytnngcn 60
 gcnggnacnc cngcnytnngg ngaygaymgn ggnmgncnt gccngcnws nytnngcngcn 120
 ytngcnytnng ayggnaaryt nmgnacngay wsnaaygcna cngcngcngc nwsnacngay 180
 ttyggnaaya thacnwsngc nytnccngcn gcngtnytnnt ayccnwsnws nacngngngay 240
 ytngtngcny tnytnwsngc ngcnaaywsn acnccnggnt ggccntayac nathgcntty 300
 mgnggngmng gncaywsnyt natggngcar gcnttygcnc cnggnggngt ngtngtnaay 360
 atggcnwsny tnggngaygc ngcngcnccn ccnmgnatha aygtnwsngc ngayggngmgn 420
 taygtngayg cnggnggnga rcargtntgg athgaygtny tnmngcnws nytnngcnmgn 480
 ggngtngcnc cnmgnwsntg gaaygaytay ytntayytna cngtnggngg nacnytnwsn 540
 aaygcnggna thwsnggna rgcnttymgn cayggncnc arathwsnaa ygtnytnngar 600
 atggaygtna thacnggna yggngaratg gtnacntgyw snaarcaryt naaygcngay 660

15

20

25

ytnttygayg cngtnytnngg nggnytnngn carttyggng tnathacnmg ngcnmgnath 720
 gengtngarc cngcnccngc nmngncnmgn tgggtmngnt tygtntayac ngayttygcn 780
 gcnttywsng cngaycarga rmgnytnaen gncncnmgc cngggnggg nggngcnwsn 840
 ttyggncna tgsntaygt ngarggnwsn gtnttygtna aycarwsnyt ngcnacngay 900
 ytngcnaaya cnggnttytt yacngaygen gaygtngcnm gnathgtngc nytngcnggn 960
 garmgnaayg cnacnacngt ntaywsnath gargcnacny tnaaytayga yaa ygcnacn 1020
 gcngcngcng cngcngtnga ycargarytn gcwsngtny tnggnaacnyt nwsntaygt 1080
 garggnttyg cnttycarmg ngaygtngcn taygcngcnt tyYtngaymg ngtncaayggn 1140
 gargargtng cnytnaayaa rytnggnytn tggmgngtnc ncayccntg gytnaayatg 1200
 ttygtncnm gnwsnmgnat hgcngaytty gaymgnggng tnttyaargg nathytnear 1260
 ggnacngaya thgtnggncc nytnathgt 1320
 ggnatgwsng cngcnacncc nwsngargay gtnttytayg cngtnwsnyt nytnttywsn 1380
 wsngtngcnc cnaaygayyt ngcnmgnytn cargarcara aymgnmgnat hytnmgntty 1440
 tgygayytng cnggnathca rtayaaraen tayytngcnm gncayacnga ymgwnsngay 1500
 tgggtmngc aytyggngc ngcnaartgg aaymgnttyg tngaratgaa raayaartay 1560
 gayccnaarm gnytnytnws nccngngcar gayathttya ay 1602

5	<210> 11 <211> 32 <212> DNA <213> Zea mays	32
	<400> 11 tgggaattcc atggggagat ggtgacgtgc tc	
10	<210> 12 <211> 33 <212> DNA <213> Zea mays	
	<400> 12 gccgtccac atggatttgt tgagggggta gac	33
15	<210> 13 <211> 37 <212> DNA <213> Zea mays	
20	<400> 13 ctcaacaaat ccatgtggga cgacggcatg tcggcgg	37
25	<210> 14 <211> 39 <212> DNA <213> Zea mays	

	<400> 14	gcggtctaga tctaactaaa acatgcatgg gctatcatc	39
5	<210> 15		
	<211> 33		
	<212> DNA		
	<213> Zea mays		
	<400> 15		
	atgggaattc catggggaga tggtgacgtg ctc		33
10	<210> 16		
	<211> 39		
	<212> DNA		
	<213> Zea mays		
15	<400> 16	gcggtctaga tctaactaaa acatgcatgg gctatcatc	39
	<210> 17		
	<211> 17		
	<212> DNA		
	<213> Zea mays		
20	<400> 17	ccggttttgg taccggt	17
	<210> 18		
	<211> 17		

	<212> DNA	
	<213> Zea mays	
	<400> 18	17
	catgaccggt accaaaa	
5	<210> 19	
	<211> 22	
	<212> DNA	
	<213> Zea mays	
10	<400> 19	22
	gacaccattc caagcatacc cc	
	<210> 20	
	<211> 22	
	<212> DNA	
	<213> Zea mays	
15	<400> 20	22
	gttctcacta gaaaaatgcc cc	

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US96/15844

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/53 C12N15/82 C12N15/81 C12N9/06 C12N1/21
C12N1/19 C12N5/10 A01H5/00 C12Q1/26

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N A01H C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHEMICAL ABSTRACTS, vol. 119, no. 21, 22 November 1993 Columbus, Ohio, US; abstract no. 221752, BURCH, L. R. ET AL: "Cytokinin oxidase and the degradative metabolism of cytokinins" XP002086612 see abstract & PHYSIOL. BIOCHEM. CYTOKININS PLANTS, SYMP. (1992), MEETING DATE 1990, 29-32. EDITOR(S): KAMINEK, MIROSLAV;MOK, DAVID W. S.; ZAZIMALOVA, EVA. PUBLISHER: SPB ACAD. PUBL., THE HAGUE, NETH. CODEN: 59KXA9, --- -/--	1-4

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

3 December 1998

Date of mailing of the international search report

18. 01. 99

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

MADDOX, A

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHREIBER B M N ET AL: "Polyclonal antibodies to maize seedling cytokinin oxidase" ANNUAL MEETING OF THE AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, CHARLOTTE, NORTH CAROLINA, USA, JULY 29-AUGUST 2, 1995. PLANT PHYSIOLOGY (ROCKVILLE) 108 (2 SUPPL.). 1995. 80., XP002086604	1-4
A	see the whole document ---	5-24
X	BURCH, LINDSAY R. ET AL: "The purification of cytokinin oxidase from Zea mays kernal's" PHYTOCHEMISTRY (1989), 28(5), 1313-19, XP002086605	1-4
Y	see the whole document ---	5-24
Y	MEILAN R ET AL: "Cloning the cytokinin oxidase gene." ANNUAL MEETING OF THE AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, PORTLAND, OREGON, USA, JULY 30-AUGUST 3, 1994. PLANT PHYSIOLOGY (ROCKVILLE) 105 (1 SUPPL.). 1994. 68., XP002086606 see the whole document ---	5-24
Y	MIROSLAV KAMINEK: "PROGRESS IN CYTOKININ RESEARCH" TRENDS IN BIOTECHNOLOGY, vol. 10, no. 5, 1 May 1992, pages 159-164, XP000272384 see page 162 ---	5-24
P,X	MORRIS, R.O, ET AL.: "Zea mays cytokinin oxidase (ckx1) gene, complete cds" EMBL SEQUENCE ACCESSION NO. AF044603, 27 July 1998, XP002086607 see the whole document ---	1-11
A	WANG, J. ET AL: "Cytokinin oxidase purification by affinity chromatography and activation by caffeic acid" PLANT SCI. (SHANNON, IREL.) (1995), 112(2), 161-6, XP002086608 see the whole document ---	1-24
A	MOTKYA, V., ET AL.: "Changes in cytokinin content and cytokinin oxidase activity in response to derepression of ipt gene transcripton in transgenic tobacco calli and plants" PLANT PHYSIOLOGY, vol. 112, 1996, pages 1035-1043, XP002086609 see the whole document ---	1-24
	---	-/--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CRESPI, M., ET AL.: "Hypothetical 47.9 kD oxidoreductase in fasciation locus(ORF5)" SWISSPROT ACCESSION NO .P46377, 1 November 1995, XP002086610 see the whole document ---	1-4
A	CRESPI., M., ET AL.: "R. fascians (D188) genes for P450 cytochrome, isopentenyltransferase and ferridoxine" EMBL ACCESSION NO. Z29635, 15 February 1994, XP002086611 see the whole document -----	5-10

